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BACKGROUND:  Limb wound on horses are often slow to heal and are prone to developing 
exuberant granulation tissue (EGT) and close primarily through epithelialization, which 
results in a cosmetically inferior and less durable repair.  In contrast, wounds on the body 
heal rapidly and primarily through contraction and rarely develop EGT.  Intravenous (IV) 
multipotent mesenchymal stromal cells (MSCs) are promising.  They home and engraft to 
cutaneous wounds and promote healing in laboratory animals, but this had not been 
demonstrated in the horse.  Furthermore, the clinical safety of administering >1.00 x 108 
allogeneic (allo) MSCs IV to a horse has not been determined. 
PILOT PROJECT: A proof-of-principle pilot project was performed with two horses that 
were administered 1.02 x 108 fluorescently labelled allo-cord blood-derived MSCs (CB-
MSCs) following surgical wound creation on the forelimb and thorax.  Results confirmed 
preferential homing and engraftment to wounds with persistence of CB-MSCs at 33 days 
following wound creation, without clinically adverse reactions to the infusion. 
SECONDARY PROJECT: A minor secondary project was developed from the pilot project, 
where the mRNA of the inflammation-associated proteins β-arrestin-2 (βarr2), CXC ligand 
(CXCL) 8, CXC receptor (CXCR) 2, CXCL10, and CXCR3 was compared in limb and thoracic 
wounds.  Results suggest that there are differences in expression between βarr2 and 
CXCL8/CXCR2 in limb and thoracic wounds. 
MAJOR PROJECT:  
Materials and Methods: Wound were surgically created on the forelimbs of treatment and 
control horses.  1.51 – 2.46 x 108 allo-CB-MSCs were administered to treatment horses 12 
hours after wound creation and were monitored for clinically adverse reactions during 
infusion.  Control horses were administered diluted cellular suspension medium (HTS-FRS) 
only.  Biopsies of the wounds were collected on days 0, 1, 2, 7, 14, and 28 from treatment 
and control horses.  The biopsies tissue was dived – a portion was snap frozen and analyzed 
using multiplex mRNA assays for proinflammatory (TNFα, CXCL8), anti-inflammatory (IL-4, 
IL-8), inflammation resolving INFγ, CXCL10), profibrotic (TGFβ1, TGFβ2), and anti-fibrotic 
(TGFβ3) cytokines, and the other portion was evaluated histologically and given a 
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combined repair and inflammation score.  The wounds were photographed on days 7, 14, 
and 28 and evaluated for wound size and total percentage of wound closure by contraction 
and epithelialization using planimetric analysis.  Day of wound closure was recorded when 
the granulation tissue was covered with epithelium.  Rate of wound closure, percentage of 
contraction, percentage of epithelialization, and mean fold change of cytokines was 
evaluated using generalized estimating equations for an overall treatment effect over all 
days (P≤0.2) and pairwise comparison for treatment effect at individual days (P≤0.05). 
Results: 3/6 (50%) treatment horses and 1/6 (17%) control horses experiences clinically 
adverse responses during injection.  Day to wound closure was not significantly improved 
(treatment 26+/- 4 days, control 27 +/- 3 days; two sample T-test, P=0.702), although 
overall wound size (GEE; P=0.145) was decreased, characterized by overall increased 
contraction (GEE; P=0.145) and decreased epithelization (GEE: P=0.015) with significantly 
less epithelization on day 14 (GEE, PWC; P=0.0173).  Histologic repair score was not 
improved and virtually identical between groups, thus no static analysis was performed.  
There was overall decrease in proinflammatory (GEE; P=0.032), anti-inflammatory (GEE; 
P=0.022), inflammation resolving (GEE; P=0.033) and profibrotic (GEE; P=0.191) cytokines 
with significantly less proinflammatory cytokines on day 2 (GEE; P=0.0003).  There was no 
difference in antifibrotic cytokines. 
CONCLUSIONS: Administered >1.51 x 108 IV allo-CB-MSCs suspended in HTS-FRS can 
induce infusion reactions in recipients which may be caused by antigenic stimulation or the 
suspension medium.  IV allo-CB-MSC therapy did not improve time to wound closure or 
histologic repair scores, although overall wound size was smaller due to increased 
contraction and decreased epithelization.  IV allo-CB-MSCs decreased expression of all 
cytokines except for antifibrotic cytokines.  Although minor improvements in wound 
healing were measured, the advantages of IV allo-CB-MSC therapy likely do not justify the 
risks of infusion reactions.  Investigation into other methods of MSC delivery and therapies 
are warranted. 
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1.  INTRODUCTION 
Horses and humans have been intimately connected for many thousands of years, with the 
first evidence of domestication having occurred over five thousand years ago1,2.  At first, the 
horse was domesticated for a source of food, but eventually its usefulness for 
transportation and labour was realized and, with the introduction of the harness and collar, 
revolutionized agriculture and advanced society1. 
Domesticating horses necessitates restraining them in enclosures to keep them in close 
proximity, but their innate flighty temperament paired with the confinement of stables and 
paddocks increases the likelihood of injury that they would not normally encounter in their 
natural environment.  Furthermore, selective breeding for traits to excel at various 
disciplines, such as pulling, riding, or racing, resulted in a variety of breed phenotypes that 
diverge drastically from their wild pony-like ancestors2–4, potentially at the expense of loss 
of fitness in other areas, such as wound healing3,4.  Clinically, it has been long observed that 
ponies, despite being the same species as horses, have superior healing characteristics to 
horses, particularly in regards to wounds on the limb, and these observations have been 
confirmed with several seminal studies4–8.  Whether the horse’s propensity for impaired 
wound healing is because of selective breeding for desired traits at the expense of healing 
characteristics or is merely reflective of manmade enclosures that the horse is not evolved 
to be confined in is to be debated.  Regardless, wounds and their related complications is 
the most common medical condition in horses, accounting for nearly 50% of all injuries in 
one report9.  In addition to being a financial burden on the client, wounds can limit a horses 
functional career and be chronically painful or even life threatening in some 
circumstances10.  Therefore, investigating methods to accelerate and improve wound 
healing is advantageous to the client and horse alike. 
Regenerative medicine including multipotent mesenchymal stromal cells (MSCs) have 
become mainstream ancillary therapies for a variety of injuries such as tendon and 
ligament injuries, osteoarthritis, and wounds11–14.  It was previously believed that MSCs 
improved healing outcomes by differentiating into supportive cells and integrating into the 
repair, but the current understanding is that MSCs impart their positive effects primarily 
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through signaling the release of inflammatory mediators to direct the normal sequence of 
healing12–17. However, despite their mainstream use in equine medicine, evidence of their 
efficacy compared to conventional therapies is still being elucidated13,14,18.  In particular, the 
use of MSCs for improving cutaneous wound healing is especially lacking, with most related 
published literature involving case reports12,19 and a single randomized control study20.  
Variables such as the source of MSCs, effective cell dose, route of administration, timing of 
administration, and number or treatments required for a measurable clinical effect are still 
not clear13,14,18.  Additionally, although MSC therapy is generally considered to be safe, 
complications associated with administration are still possible and need to be further 
investigated14,21.   
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2.  LITERATURE REVIEW 
2.1 The Physiology of Wound Healing 
In all mammals, the skin acts as a protective barrier to prevent contamination and infection 
of the underlying tissues with environmental debris and pathogens.  In the event that the 
skin is wounded, such as with disease or injury, the body must repair it both efficiently and 
effectively or risk infection that could compromise the entire organism and potentially lead 
to death of the individual.  
Regardless of species, the basic principles of full-thickness cutaneous wound healing are the 
same amongst mammals.  If a wound is sutured closed shortly after injury, it heals with 
little granulation tissue formation and epithelialization between the sutured edges and 
forms a minimal scar.  Conversely, during second intention healing, the wound edges are 
not apposed and the wound fills first with granulation tissue followed by contraction of the 
skin edges and migration of keratinocytes from the outside borders to the center of the 
wound over the surface of the granulation bed10,22.  Second intention healing is considered 
less desirable compared to primary intention healing as the healing process is prolonged, 
and has a larger scar that lacks sebaceous and apocrine glands in the epithelialized portion, 
causing the dermis to be functionally and cosmetically inferior.  Furthermore, complications 
are more likely to occur which has both humane and financial implications for the horse 
and client10,23,24.  
Cutaneous wound healing is a complex integrative process with several phases that are not 
independent from one another, but rather happen concurrently in a sequential fashion.  
These phases are hemostasis, inflammation, cellular proliferation, and remodelling10,15,22.  It 
is important that these phases are initiated and concluded at the correct time points during 
the healing process or the effectiveness of the repair can be compromised.  The release of 
various inflammatory mediators at the correct time and amounts is critical to ensuring the 
progression of healing without complication (Table 2.1)10,15,22. 
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Table 2.1 – Inflammatory Mediators Involved in Cutaneous Wound Healing10,22,25–27 
Name Overall effect Functions 
TNFα Proinflammatory x Leukocyte chemotaxis 
x Activate other mediators 
CXCL8/CXCR2 Proinflammatory x Neutrophil chemotaxis 
x Angiogenesis 
x Epithelialization 
IL-10 Anti-inflammatory x Suppress release of proinflammatory 
mediators 
IL-4 Anti-inflammatory x Suppress release of proinflammatory 
mediators 
x M2 phenotype differentiation 
x Downregulate CXCR2 on neutrophils 
x CXCL8 release for angiogenesis and 
epithelialization 
CXCL10/CXCR3 Inflammation resolving x Angiostatic 
x Monocyte and T lymphocyte 
chemotaxis 
IFNγ Inflammation resolving x CXCL10 release 
x M1 phenotype differentiation 
TGFβ1/TGFβ2 Profibrotic x Induce Type III collagen deposition 
x Upregulate TIMPs 
TGFβ3 Antifibrotic x Decrease Type III collagen deposition 
x Promote Type I collagen formation 
and cross-linking 
x Upregulate MMPs 
βarr2 Inflammation 
regulation 






When a cutaneous wound is created, vessels are disrupted and begin to haemorrhage.  
Arachidonic acid is released from the phospholipids of traumatized endothelial cells, which 
triggers the release of mediators that induces vasospasm and activates the endothelial 
surface to promote aggregation of platelets.  Collectively, this initial vascular phase causes 
arteries and arterioles to constrict and a platelet plug to form, stymying blood loss.  Shortly 
afterwards, smaller arterioles and venules vasodilate by relaxing smooth muscle and 
opening gap junctions between endothelial cells in response to mediators released from the 
damaged endothelium and platelet granules.  This allows growth factors, cytokines, 
platelets, and inflammatory cells to infiltrate the wound site and initiate the proper cascade 
of events for healing.  A blood clot forms as a result of both the intrinsic and extrinsic 
clotting cascades.  The blood clot is referred to as the provisional extracellular matrix, 
which serves as a scaffold for cell migration and stromal components during subsequent 
healing phases.  Over time, as the clot desiccates, an eschar or “scab” is formed which acts as 
a biological bandage that will slough as healing continues beneath10,22. 
2.1.2 Inflammation 
Inflammation is a critical phase of healing as it debrides and prepares the wound bed for 
subsequent phases while continuing to release inflammatory mediators crucial for 
progression and resolution of healing.  Platelet degranulation plays a pivotal role initiating 
this process by releasing a myriad of mediators, the most notable in regards to this review 
being tumour necrosis factor-alpha (TNFα) and those of the transforming growth factor-
beta (TGFβ) class, which trigger release of other chemotactic proinflammatory mediators 
from adjacent activated cells10,15,22.  Resident tissue macrophages, circulating neutrophils 
and monocytes, and adjacent fibroblasts are drawn to the wound site.  The early 
inflammatory phase is characterized by the appearance of neutrophils at the wound site, 
followed by the late inflammatory phase that is characterized by the recruitment of both 
local resident macrophages and circulating monocytes10,15. 
TNFα triggers the release of chemokine (C-X-C motif) ligand (CXCL) 8 from surrounding 
activated cells.  CXCL8 is a potent chemoattractant of neutrophils; it upregulates expression 
of its receptor chemokine (C-X-C motif) receptor (CXCR) 2 on the neutrophil surface while 
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also inducing further CXCL8 release from neutrophils themselves25.  During the early 
inflammatory phase, neutrophils infiltrate the wound immediately following injury and 
peak at approximately forty-eight hours post injury.  Neutrophils eliminate the wound of 
debris and bacteria through phagocytosis.  Once the wound is cleared of contamination, 
recruited neutrophils apoptose and are either phagocytized by macrophages or become 
apart of the eschar that will later be shed during epithelialization10,15,22. Although powerful 
warriors in the war against infection, neutrophils are not vital to healing of non-infected 
wounds28,29.  However, CXCL8 is vital for initiating angiogenesis and epithelialization and 
reduced neutrophil recruitment contributes to impaired healing29,30. 
Macrophages follow neutrophil infiltration and peak within seventy-two hours15,22.  
Macrophages are orchestral conductors in the remainder of the healing process and their 
roles change and adapt as healing progresses.  There are three recognized phenotypes of 
macrophages: the classic M1 phenotype that primarily promotes inflammation through 
release of proinflammatory mediators and antigen presentation to lymphocytes; the 
“resolving” phenotype that releases resolving and anti-inflammatory mediators while 
continuing to debride the site; and the interleukin (IL)-4 activated M2 phenotype that 
stimulates and drives the proliferative phase of healing10,31.  Macrophages are derived from 
two distinct and separate classes of cells - the bone marrow-derived monocyte, or the 
embryonic-derived resident tissue macrophage32.  Resident tissue macrophages are self-
replenishing and play an important role first by recruiting circulating monocytes at the time 
of injury then returning the wound to normal homeostasis after the initial inflammatory 
stage is complete.  The resident tissue macrophage is also vital for initiating and 
maintaining the correct sequence of events and minimizing scar formation31.  Interestingly, 
the dermis is nearly devoid of embryonic-derived resident tissue macrophages and requires 
constant recruitment from circulating monocytes, who cannot replenish themselves once 
inflammation resolves33.  This physiologic phenomenon may partly explain why the dermis 
is prone to excessive fibrosis and scarring compared to other tissues such as bone34.  
Because macrophages simultaneously eliminate redundant neutrophils and stimulate 
repair, their presence and action serves as an important transition between the 




Three distinct yet interconnected processes define proliferation: fibroplasia, angiogenesis, 
and epithelialization.  These processes occur simultaneously and each is dependent on the 
other to be executed effectively10,22. 
Fibroplasia is characterized by infiltration of fibroblasts into the provisional matrix.  
Immediately at the time of injury, fibroblasts migrate through self-created proteolytic 
pathways into the provisional matrix and proliferate in response to several different 
mediators including the TGF class22 and IL-425.  Approximately three days after injury, these 
fibroblasts produce constituents of the extracellular matrix to form immature type III 
collagen.  As collagen is produced, the wound becomes exponentially stronger over the 
following seven to fourteen days.  Replacement of the provisional matrix with the collagen 
rich extracellular matrix creates granulation tissue, a distinguishing characteristic of 
proliferation.  Granulation tissue acts as a physical barrier to infection and a robust scaffold 
into which various inflammatory and regenerative cells can migrate.  Once enough collagen 
is created, fibroblasts stop producing and either convert into contractile myofibroblasts or 
apoptose10,22.   
Angiogenesis is the creation of new vessels from the previously injured vessels to provide 
nutrients and oxygen to the collagen producing fibroblasts.  At the immediate time of injury, 
endothelial cells upregulate CXCR2 and initiate neovascularization in response to several 
mediators including the TGFβ class22 and CXCL825 while in the absence of neighbouring 
endothelial cells10.  At approximately day three, hypoxia and lactate further stimulates 
angiogenesis and vascular buds will follow the proteolytic paths created by the migrating 
fibroblasts into the wound bed.  These new vessels are what gives granulation tissue its 
characteristic pink color10,15,22.  Mature granulation tissue becomes pale in color when 
vessels regress as hypoxia and lactate tension resolves and CXCR3 upregulates in response 
to interferon-gamma (INFγ) inducible angiostatic mediators including CXCL1010,25. 
Epithelialization is an integral component of wound closure.  Keratinocytes proliferate, 
regenerate, and begin migration within hours of injury. Hemidesmosomes that bind 
keratinocytes to one another and the underlying dermis disintegrate to allow the cells to 
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migrate across the granulation bed as it forms10.  Similar to endothelial cells, keratinocytes 
proliferate, upregulate CXCR2, and migrate to the center of the wound in the absence of 
neighbouring cells and in response to several different mediators also including CXCL810,25. 
As the keratinocytes migrate centripetally, they dissect between the eschar and the 
granulating provisional matrix by secreting proteinases, causing the eschar to eventually 
slough.  Once the keratinocytes meet in the center of the wound, proliferation stops and the 
cells express laminin, a protein that binds the new epithelial layer to the underlying 
granulation tissue10.   
2.1.4  Remodelling 
Remodelling is the final stage of healing and can take up to two years to complete10,15.  
Contraction of the wound edges and structural changes to the extracellular matrix occur 
simultaneously to create a strong and functional repair.  It is during remodelling that the 
final strength of the repair is achieved although is never greater than 80% of the original 
strength of unwounded skin10,22.   
As with epithelialization, contraction is important for facilitating wound closure.  
Contraction is the centripetal movement of full thickness skin toward the centre of the 
wound, effectively reducing the total area requiring epithelialization to complete the 
closure10.  As fibroblasts migrate into the wound, many will change their phenotype to 
become myofibroblasts in response to many mediators including TGFβ1.  These cells are 
primarily responsible for contraction10,22.  Contraction of the wound is important, as it is 
stronger and cosmetically superior to a wound that heals primarily through 
epithelialization because it maintains apocrine and sebaceous glands.  For the first two 
weeks while the myofibroblasts are transforming and infiltrating the wound bed, the 
wound edges will first retract and the surface area of the wound becomes larger; this is 
known as the lag phase.  Following the lag phase, there is a rapid contraction phase where 
the wound gets noticeably smaller from day to day as the myofibroblasts contract, then a 
slow contraction phase where closure of the wound is less apparent.  Contraction will cease 
when one of the following three criteria are met: keratinocytes meet at the center of the 
wound; tension of the tissue surrounding the wound is equivalent to or exceeds the 
contractile forces of the myofibroblasts; the number of myofibroblasts in the wound bed 
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are insufficient to fully contract the wound despite the surrounding skin not having 
excessive tension, as is the case with chronic wounds.  Once contraction is complete, 
myofibroblasts will either change their phenotype back to fibroblasts or apoptose10. 
Remodelling is a fine balance between synthesis and degradation of the matrix.  The M2 and 
resolving resident tissue macrophage phenotypes are integral to this process.  M2 
macrophages are activated by IL-4 released from T helper cells that causes the M2 
macrophages to release remodelling mediators including those of the TGFβ family30,31.  IL-4 
also causes release of CXCL8 to further stimulate angiogenesis and epithelialization while 
downregulating CXCR2 on the neutrophil surface through intracellular β-arrestin-2 (βarr2) 
mediated endocytosis, preventing further neutrophil migration25,27,35.  Resolving 
macrophages are activated by phagocytizing apoptotic neutrophils and release anti-
inflammatory mediators such as IL-10 as well as more TGFβ30,31.  There are three primary 
cytokines of the TGFβ family.  TGFβ1 and TGFβ2 are primarily profibrotic and induce 
fibrosis, while TGFβ3 is antifibrotic and is associated with a scarless repair36.  The correct 
equilibrium of these profibrotic and antifibrotic cytokines is necessary to promote a repair 
that rapidly gains strength without having excessive scarring.  Over time through the action 
of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs), 
collagen is converted from the haphazardly deposited immature type III to the uniformly 
linear mature type I with increased cross-linking between fibres.  Eventually, the 
parenchyma will take on a more normal histologic appearance and an acellular scar will 
form10,15.  
2.2  Wound Healing of the Distal Limb Compared to the Body 
Location of a wound can drastically impact the progression of healing as well as the overall 
outcome in the horse24.  Limb wounds are much more likely to develop complications and 
have impaired healing characteristics compared to wounds on the body24.  Contraction and 
epithelialization contribute to wound closure on the limb by approximately 30% and 70%, 
respectively, whereas the inverse is observed on the body6.  Additionally, epithelialization is 
slower in limb wounds than body wounds, with limb wounds producing epithelium at only 
approximately 75% of the rate of body wounds10.  Remodelling and maturation is also 
dysregulated as the final repair only gains 60% of the strength of non-wounded skin37. Limb 
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wounds also have a much higher propensity to develop exuberant granulation tissue (EGT), 
a fibroproliferative disorder where granulation tissue expands above and beyond the 
borders of the wound24.  Why limbs wounds have delayed healing and are more likely to 
develop EGT is likely multifactorial with anatomic, physiologic, and genetic components.   
Anatomically, the distal limb has many high motion joints whose movement counters the 
action of myofibroblasts within a wound, and limb wounds are more likely to be 
contaminated with debris and fecal material than body wounds because of their proximity 
to the ground. This induces chronic inflammation and impairs healing38. Recent studies 
have determined that limb wounds have different microbiota compositions than body 
wounds - specifically, higher levels of Fusobacterium and Actinobacillus spp.,39 - and 
consistently develop biofilm whereas body wounds appear much less prone40.  Although 
bacterial colonization likely hinders healing, other features unique to the limb also 
contribute to slower healing. 
Histologically, the epidermis on limbs is nearly a third thicker than on the body and has an 
accessory-cordovan layer comprised of thickened collagen bundles that is absent in the 
body41.  This may cause the skin on the limb to be less elastic than that on the body and 
resist contraction41. Myofibroblasts in limb wounds are haphazardly organized rather than 
in ordered linear patterns as in body wounds and contraction is consequently less 
effective5,7,24.  Furthermore, oxygen saturation is consistently lower in wounds on the limb 
than on the body, despite increased neovascularization.  Hypoxia induced angiogenesis is a 
normal expected physiologic response, but angiogenesis is abnormal in EGT as the 
microvessels are often occluded secondary to endothelial hypertrophy.  Because occluded 
microvessels are unable to maintain aerobic metabolism, hypoxia persists which 
paradoxically exacerbates dysfunctional angiogenesis. Hypoxia is also a potent upregulator 
of TGFβ1, which stimulates fibrosis and further occludes microvessels, triggering a self-
perpetuating cycle24,42,43.  Prolonged elevations of TGFβ1 is a defining trait in limb wounds44 
and is even more pronounced in EGT45, a phenomenon that is likely driven by hypoxia. 
Acute inflammation is less pronounced and more prolonged in limb wounds.  This is partly 
due to the local hypoxic environment that restricts the oxidative burst within the neutrophil 
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phagolysosome required for bacterial killing.  Inflammation is then perpetuated by the 
resulting biofilm formation and increased oxygen consumption by the biofilm itself 24,40. 
However, impairment of the initial inflammatory response to injury and resolution of 
inflammation is also largely driven by the inherently inferior immune response in the horse 
that is not seen in ponies4,24. 
Genetically, ponies and horses are the same species and yet ponies have superior healing 
characteristics4.  Ponies are technically less than 14.2 hands (58 inches; 147 centimeters) 
tall at the withers, but improved wound healing appears to be unique in stocky phenotypes 
rather than simply small horses, suggesting that the horse’s healing deficiency has been 
inadvertently enhanced by selective breeding for other desired traits3,4.  In ponies, limb 
wounds have delayed healing compared to body wounds, but not to the same extent as 
horses, with limb wounds healing with approximately 50% contraction and 50% 
epithelialization4,6. Both ponies and horses alike develop EGT when limb wounds are 
bandaged, highlighting the importance of hypoxia in contributing to EGT formation.  
However, EGT resolves and wounds continue to heal normally when the wounds are 
uncovered in ponies, whereas horse limb wounds often require debridement and advanced 
wound management to resolve the EGT and promote healing24. 
An inadequate acute inflammatory response and delayed resolution of inflammation 
predisposes horses to EGT formation.  Polymorphonuclear cells (PMNs) isolated from 
ponies have a more pronounced release of the proinflammatory mediators TNFα and IL-1 
and higher production of reactive oxygen species compared to horse PMNs8.  An inadequate 
initial proinflammatory response delays the release of TGFβ1, which in turn delays 
differentiation of fibroblasts into myofibroblasts and inhibits epithelialization, which is 
further inhibited by continued release of TGFβ1 by fibroblasts24.  In addition, weak 
recruitment of neutrophils leads to fewer apoptotic neutrophils available to trigger 
differentiation of macrophages into resolving and M2 anti-inflammatory phenotypes and 
release of antifibrotic TGFβ3, allowing for prolonged low-grade profibrotic inflammation 




Also interesting to note is the reduced rate of fibroblast apoptosis in limb EGT compared to 
granulation tissue on the body.  Ordinarily when cells become acutely hypoxic, they 
apoptose to prevent necrosis within the wound.  This is facilitated by p53, a tumour 
suppressor protein that downregulates expression of the gene bcl-2, an inhibitor of 
apoptosis.  However, if hypoxia is introduced gradually, such as during dysfunctional 
angiogenesis in EGT, bcl-2 will instead become upregulated and inhibit apoptosis.  
Furthermore, mutated p53 produced by keratinocytes no longer inhibits bcl-2, thus 
apoptosis does not take place at ordinary rates and EGT proliferates unabated43.   
2.3  Exuberant Granulation Tissue in Horses and Keloids in Humans  
Horses have been proposed as animal models for studying keloids in humans as horses and 
people are the only two known species that develop spontaneous fibroproliferative 
disorders46.  Contrary to EGT in horses, keloids are epithelialized and have characteristic 
thickened hyalinised collagen, known as keloidal collagen, that is absent in EGT46,47.  
However, EGT shares many similarities with keloids and it is important to understand the 
etiology of keloid formation as it may provide insights to why EGT develops in horses.   
Keloids are highly proliferative fibroblastic growths that occur after trauma and, similar to 
EGT, expand beyond the border of the original wound48.  Healing limb wounds share similar 
profibrotic and antifibrotic cytokine profiles, specifically elevated TGFβ1 and decreased 
TGFβ3 expression44,45.  Both keloids and EGT have a genetic component; horses are much 
more likely to develop EGT than ponies4,24 and keloids develop nearly solely in dark 
skinned individuals with familial inheritance patterns49.  In addition, both keloids and EGT 
tend to form in areas of high skin tension, such as on the chest and back of humans48 and 
the distal limbs of horses24.   
However, one of the most common areas of keloid formation is the earlobe, an area with 
arguably little tension48.  The earlobe, chest, and back contain many sebaceous glands and 
theories suggest that autoimmune disease or delayed hypersensitivity response to sebum 
and/or sebaceous glands may also be a component in keloid formation48,50.  As far as the 
author is aware, the possibility of horse EGT formation having a similar autoimmune 
mediated pathogenesis has not yet been investigated and exploring this avenue may 
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provide further clues as to say why horses develop EGT as well as provide avenues for 
further treatment options such as anti-allergic pharmaceuticals.  
2.4  Multipotent Mesenchymal Stromal Cells and Cutaneous Wound Healing 
Currently EGT is treated with serial debridement to lessen the bacterial load, topical 
corticosteroids to tamper the protracted chronic inflammatory response, and even skin 
grafting in stagnant cases24.  These treatment protocols are typically eventually successful, 
but are expensive and labour intensive and not without harm and discomfort to the patient.  
Therefore, therapies that may accelerate wound healing and prevent EGT formation are 
warranted.  
Multipotent mesenchymal stromal cells (MSCs) are being investigated as adjunct 
regenerative therapy to accelerate and/or improve the quality of cutaneous wound 
healing15,51 and for treating keloids52,53 in humans with promising preliminary results.  In 
equine regenerative medicine, MSCs have been used primarily in tendon and ligament 
injuries11, but research examining their effects in equine cutaneous wound healing is still in 
its infancy.  In vitro, equine MSCs promote healing in wound scratch assays54 and block the 
fibrogenic response of fibroblasts to TGFβ155.  Furthermore, MSCs secrete antimicrobial 
peptides that have direct antibacterial effects against common wound pathogenic 
contaminants56 which may assist in healing of contaminated limb wounds.  In vivo, 
however, only a experimental study has been performed examining the effects of topical 
and subcutaneous MSCs in cutaneous limb wounds in horses20.  In that study, treated 
wounds had improved histologic healing scores and healing times than control wounds.  
These results are promising, but more in vivo studies are needed to fully determine and 
understand their effects. 
2.4.1 Definition and Characterization 
MSCs are derived from the mesoderm and can be isolated from adult or embryonic sources.  
According to the International Society for Cellular Therapy (ISCT), human MSCs are plastic 
adherent, express the surface markers cluster of differentiation (CD)73, CD90, and CD105, 
do not express CD11b/CD14, CD19/CD79a, CD34, CD45, and major histocompatibility 
complex (MHC)-II, and can differentiate into osteogenic, lipogenic, and chondrogenic 
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lineages under appropriate culture conditions12,57,58.  The term “stem cell” is reserved for 
those cells that meet the above criteria, but also have demonstrated characteristics of true 
“stemness” in vivo; specifically, long term survival, self-renewal, and spontaneous 
differentiation57,58.  The ISCT’s position statement can be broadly applied to the horse 
although equine MSCs variably express other surface makers (CD29, CD90, CD44, CD166, 
CD13, CD146, CD117, CD40, CD80, CD73, CD105)12,59,60 which is thought to be related to 
species variation and differences in antibody cross-reactivity12,57 (Table 2.2). 
2.4.2  Sources 
Conventionally, MSCs are isolated in the horse from bone marrow or adipose tissue, 
although MSCs have also been isolated from synovium, muscle, gingiva, dental pulp, 
periodontal ligament, endometrium, hair follicles, peripheral blood, and the umbilical 
cord12.  Umbilical cord blood is an attractive source as collection is non-invasive59,61, cells 
are potentially more pluripotent and proliferative than other adult sources59,61, have 
immunomodulatory effects in vitro59,61,62 and in vivo63,64, and can be cryopreserved and 
stored for future use62. Equine umbilical cord blood-derived MSCs (CB-MSCs) have 
trilineage differentiation capabilities65,66 and consistently express the surface markers 
CD29, CD44, CD90, and occasionally CD105, and lack expression of CD4, CD8, CD11a/18, 
CD73 and MHC-I and MHC-II59,67,68.  CB-MSCs have already shown promising effects in in 
vivo cutaneous wound healing20 and synovitis63 studies. 
2.4.3  Autologous versus Allogeneic 
Autologous MSCs (auto-MSCs) are collected and isolated from the same animal to which 
they are intended to be administered whereas allogeneic MSCs (allo-MSCs) are sourced 
from a different animal of the same species69.  When characterized in vitro, both auto- and 
allo-MSCs do not demonstrate MHC-I and MHC-II surface markers, suggesting that allo-
MSCs are immunoprivileged.  However, allo-MSCs consistently induce a detectable immune 
response in the horse12,70,71 and, in laboratory animal cardiac infarct models, engraft at 
lower rates and persist in the recipient for less time than syngeneic auto-MSCs72,73. It is 
believed that the inflammatory impetus triggers rejection following allo-MSC therapy 
because MHC-I and MHC-II are expressed in successfully engrafted cells that begin to 
differentiate72,73 or become activated in direct contact with endogenous mononuclear 
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Table 2.2: Summary of Defining Characteristics of Human and Equine MSCs12,57,58,67 
Criteria Human Horse 
1) Plastic adherent  
o Differentiate from hematopoietic cells (not 
plastic adherent) 
+ * + 
2) Surface markers 
 
CD73 (5’ nucleotidase) 
x Nucleoside hydrolysis + * ± 
CD90 (Thy1) 
x Cell to cell interactions + * + 
CD105 (Endoglin) 
x TGFβ receptor complex + * ± 
MHC-II 
x Antigen presentation – B 
lymphocyte, macrophage 
- * - 
MHC-I 
x Antigen presentation - All 
nucleated cells  
± ± 
CD11b/CD14 
x Bind LPS – mononuclear 
cells 
- * - 
CD19/CD79α  
x B lymphocytes - * - 
CD34 
x Primitive hematopoietic and 
endothelial cells 
- * ± 
CD45  
x All mature leukocytes  - * - 
CD29 (β1-integrin) 
x Cell adhesion + + 
CD44 
x Cell adhesion + + 
CD4 
x Helper T lymphocyte - - 
CD8 
x Cytotoxic T lymphocyte - - 




+ * + 
(*) = minimum criteria for human MSCs established by the ISCT58 
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cells71,74; therefore, allo-MSCs are considered to be temporarily immune evasive, rather 
than truly immunoprivileged75.  Despite this, allo-MSC therapy has repeatedly shown 
beneficial therapeutic effects that is nearly equivalent to autologous or syngeneic cells73,75.  
In the horse, allo-MSCs have anti-inflammatory effects in experimentally created synovitis 
models 63,76 and improved lameness grading scales in naturally occurring arthritis77,78 
compared to controls.  Furthermore, allo-MSCs improved cutaneous wound healing times 
and histologic scores compared to control wounds20, suggesting that this beneficial effect is 
transferrable wound healing in horses. 
In addition to autologous collection being invasive, isolation and expansion is a prolonged 
process18 during which the ideal time of administration to best  ameliorate the immune 
response may be missed.  In spinal contusion79 and colitis80 models using mice, the best 
clinical outcomes were when MSCs were administered during the acute inflammatory 
phase.  Allogeneic sources are attractive as collection is non-invasive, they can be expanded, 
characterized, and immune matched prior to storage, and can be administered “off-the-
shelf” shortly following an injury during the acute inflammatory phase18,62,78, which may 
result in accelerated and improved wound healing and decrease the risk of development of 
EGT, in spite of allogeneic induced immunogenicity. 
2.4.4  Administration 
MSC therapy for cutaneous wounds may be administered either locally, via topical20,81 or 
intradermal means20,82,83, and systemically16,84,85, and the method of administration may 
affect the efficacy of homing and engraftment of the cells.  Briefly, homing is 
transendothelial migration of cells to the site of injury, and engraftment is survival of the 
administered cells at the site86,87- more detail is provided in 2.4.6.  Local administration is 
intuitive, but can be technically challenging and may cause further tissue damage 
iatrogenically secondary to the needle tract and a local micro-compartmentalization 
effect16,88,89.  Local administration also does not necessarily improve engraftment rates 




Intravenous (IV) systemic administration is technically easy to perform, does not cause 
further trauma at the wound site, and administered cells have been shown to migrate, 
home, and engraft at the wound site16,17,84. However, complications following intravascular 
administration have been reported including fatal pulmonary embolism21, cerebral 
embolism90, and pulmonary edema and haemorrhage91.  In addition, following IV 
administration, the majority of cells become entrapped in the lungs, known as the “first-
pass-effect”16,79.  Regardless, IV administration in laboratory animals and humans has 
repeatedly been shown to be well tolerated16,79,80,84,85,92,93, and even if MSCs are not 
detected in the target tissue, wound healing is still improved, which is attributed to 
modulation of the systemic immune response16,79,80,85.  Furthermore, IV MSCs may be less 
immunogenic than those administered locally92.  Preliminary studies of jugular and palmar 
digital IV administration in horses show they are well tolerated12,64,71,89,94–96, but no studies 
have yet been performed to assess their effects on wounds in horses. 
2.4.5 Effective Cell Dose 
The effective cell dose of IV MSCs required to influence wound healing in horses is currently 
unknown.  To date, 5.0 x 107 is the highest cell dose administered IV to an equid71.  
Although the study was not examining cutaneous wound healing, there was evidence of 
lymphocyte allogeneic stimulation, and whether the detected immunomodulation would be 
enough to influence healing is impossible to say.  In mice, 1 x 106 IV MSCs are typically 
administered in wound healing models16.  This is equivalent to 33 x 106 cells per kilogram 
or over 14 billion for the average 450-kilogram horse.  Clearly, administering this many 
cells to a horse would be challenging to produce and cost prohibitive, but a positive effect 
cannot be expected unless doses higher than those currently reported in horses are 
explored.  
2.4.6 Homing and Engraftment 
Homing is transendothelial migration of cells following arrest within the vasculature.  
Leukocytes are most commonly referred to in regards to this process, but other cells 
including MSCs are also capable.  Following injury, both administered exogenous and native 
endogenous MSCs respond to inflammatory chemokine release at the injury site and 
actively home systemically by transmigrating through the endothelium following rolling 
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and diapedesis similar to leukocytes, albeit less efficiently86.  Following transendothelial 
migration, administered MSCs that survive and integrate into the tissue are considered to 
be “engrafted”87. 
Although it was previously believed that MSCs contributed to healing by differentiating at 
the site of injury and integrating into the repair, current theories suggest that MSCs mainly 
modulate the inflammatory environment to optimize tissue healing, both locally and 
systemically, by conducting the release of anti-inflammatory and pro-angiogenic cytokines 
and growth factors12–17.  Although successful engraftment does not seem to be critical to 
enhance healing79,80,85, engraftment of even low numbers of exogenous MSCs has prolonged 
beneficial effects compared to MSCs that did not engraft and had a single effect at the time 
of administration16,87.  Local administration does not necessarily improve engraftment, and 
does not utilize the additional benefit of systemic immunomodulation by systemic 
administration16.   The state of inflammation also plays an important role in this process 
with studies showing that MSC engraftment rates are optimized when administered during 
the acute inflammatory phase rather than the later chronic inflammatory phase73,79,80.  
Therefore, timing of administration is an important variable that should be considered to 
maximize the benefits of MSC therapy.   
2.5  Rationale 
Cutaneous wounds are one of the most common reported injuries in horses and are a 
significant welfare concern9,10.  Limb wounds in horses have different healing 
characteristics than wounds on the body related to anatomic, physiologic, and 
inflammatory differences4,24.  These differences predispose limb wounds to complications 
such as infection, EGT, and delayed healing4,24,40.  MSCs are immunomodulatory and are a 
promising therapy for promoting healing of limb wounds in horses, but clinical studies 
examining their efficacy and safety are lacking12–14.  Ideal timing of administration in 
relation to the occurrence of the wound is unknown, but studies in other species have 
determined that administration during the acute inflammatory stage is ideal for promoting 
healing in a variety of injury models73,79,80, which in the case of an unanticipated injury can 
only be achieved by administrating allogeneic sources.  Although allogeneic sources do not 
have surface expression of MHC-I and MHC-II in vitro, allo-MSCs express cell surface 
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markers following engraftment and are rapidly rejected by the host72–74.  Regardless, allo-
MSCs still positively influence healing nearly as well as auto-MSCs through modulation of 
the immune response16,73,75, and are generally well tolerated by the recipient.  There are 
many different proposed routes of delivery of MSCs, but IV is attractive primarily for its 
ease of administration compared to other methods16,17,84, and may be just as effective as 
other delivery methods despite low engraftment rates and entrapment of the cells in the 
lungs16,79,80,85.  However, homing and engraftment to cutaneous wounds following jugular IV 
administration has never been documented in horses, and may be different compared to 
other species. Pulmonary injury following IV administration is an unlikely but very serious 
complication21,91, but preliminary studies in horses have shown that this administration 
method is well tolerated12,64,71,89,94–96 although they do stimulate a cellular immune 
response in equine recipients but without a clinical adverse response71.  Furthermore, the 
effective IV cell dose to promote healing is unknown, but current published doses71,95 are 
far below the cells administered per gram to that of laboratory animals16, and investigation 
into the tolerance and efficacy of higher doses are needed.  Compared to other sources such 
as adipose-derived and bone marrow-derived MSCs, allo-CB-MSCs are promising as 
collection is non-invasive59,61, they have immunomodulatory properties in vitro and in 
vivo59,61–64,67, they are well tolerated following IV administration71, and they can be frozen 






3.  OVERARCHING HYPOTHESES AND PRIMARY OBJECTIVES 
Our overarching hypotheses are that following IV administration of >1.00 x 108 allo-CB-
MSCs: 
1) cells home and engraft to surgically created wounds. 
2) produce no adverse clinical reactions. 
3) promote macroscopic and histologic healing of limb wounds.  
4) alter the immunomodulatory cytokine profile within the limb wound environment.   
 
Our primary objectives are: 
1) determine whether IV administration of >1.00 x 108 allo-CB-MSCs causes clinically 
detectable adverse reactions. 
2) homing and engraftment of allo-CB-MSCs to surgically created limb and thoracic 
wounds over time following IV administration.   
3) determine if IV allo-CB-MSC therapy accelerates closure of limb wounds. 
4) determine if IV allo-CB-MSC therapy improves histologic healing scores of limb wounds. 
 
Our secondary objectives are: 
1) determine whether preliminary observations of mRNA expression of βarr2, 
CXCL8/CXCR2, CXCL10/CXCR3 differ between limb and thoracic wounds over time. 
2) determine whether IV allo-CB-MSC therapy alters the mRNA expression of 
proinflammatory, anti-inflammatory, inflammation resolving, profibrotic, and 




4.  HOMING AND ENGRAFTMENT OF INTRAVENOUSLY ADMINISTERED EQUINE CORD 
BLOOD-DERIVED MULTIPOTENT MESENCHYMAL STROMAL CELLS TO SURGICALLY 
CREATED CUTANEOUS WOUNDS IN HORSES:  
A PILOT PROJECT 
 
Transition Statement:  
This chapter presents the preliminary observations of homing and engraftment to surgically 
created wounds following IV administration of allo-CB-MSCs to two horses.  The intents of this 
pilot project was to determine the feasibility of shipment and fluorescently labelling large 
quantities of CB-MSCs and its effect on viability of the cells prior to commencing with the 
major project, and also determine that administering large quantities of allo-CB-MSCs would 
not negatively affect the recipients.  In addition, this pilot project intended to describe homing 
and engraftment of fluorescently labelled cells following IV administration, if present, to 
surgically created wounds on the limb and thorax to provide further insights into the 
mechanism of MSC influence on wound healing in horses. 
 
This project determined that receiving and fluorescently labelling large amounts of CB-MSCs 
using the described techniques had minimal effect on viability and was technically feasible, 
and the recipients had no clinically adverse responses.  In addition, CB-MSCs were detected in 
biopsied wound tissue and important initial observations suggest that there are differences in 
homing and engraftment between limb and thoracic wounds.   
 
4.1 Introduction 
Cutaneous wounds are common in horses and often must heal by second intention. 
Compared to body wounds, limb wounds have prolonged low-grade inflammation which 
causes slower healing and less contraction, and this in turn promotes development of 
exuberant granulation tissue (EGT) and a less durable and less cosmetic repair4,24. Keloid 
formation in humans is similar to EGT formation on the limbs of horses and, interestingly, 
humans and horses are the only two species that spontaneously develop these 
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fibroproliferative disorders, making the horse a good animal model for studying keloids and 
hypertrophic scars in humans38.   
Multipotent mesenchymal stromal cells (MSCs) have been investigated as ancillary therapy 
for complicated cutaneous healing and keloid treatment in humans15,51–53. MSCs improve 
wound healing by modulating the immune response both systemically and locally16,17,97 and 
these positive effects are further enhanced when MSCs successfully home to and engraft 
within the wound87. However, experimental studies examining the effects of multipotent 
cells on equine cutaneous wounds are limited20,98,99. 
In horses, autologous MSCs are most commonly used for tendon healing and a lag time is 
required for isolation and expansion of MSCs before administration11,18. While the most 
appropriate time for administration of MSCs to enhance healing of cutaneous wounds is 
currently unknown, spinal cord contusion79 and colitis80 models using laboratory animals 
have shown that MSC therapy during the acute inflammatory phase is crucial to best 
ameliorate the inflammatory response. Thus delaying therapy to culture autologous MSCs 
may miss the “window of opportunity” for a good outcome. Allogeneic MSCs (allo-MSCs) 
can be isolated and expanded prior to injury for timely administration18, and intravenous 
(IV) allo-MSCs have been shown to positively influence cutaneous wound healing in several 
species15,17 but this effect has not yet been demonstrated in horses. 
In human regenerative medicine, there is great interest in umbilical cord blood-derived 
MSCs (CB-MSCs) as collection is non-invasive, they can be stored long-term for future 
autologous or allogeneic use, are immunosuppressive and immunomodulatory and have 
higher expression of pluripotency markers as well as higher isolation and proliferation 
rates compared to bone marrow-derived MSCs100. Equine CB-MSCs are a very promising 
source of allo-MSCs because they can be similarly collected, stored, and expanded66 and 
have been shown to have immunomodulatory properties in vitro59,63. 
While systemic administration of MSCs is minimally invasive and convenient, complications 
such as pulmonary injury21,91, cerebral embolism90 and hypersensitivity responses101 are 
possible. Safety studies of relatively small amounts of IV administered MSCs (0.2 - 50 x 
106)64,71,95,102 have been performed in horses but to our knowledge no equine studies have 
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investigated whether there are complications associated with IV administration of >1.0 x 
108 MSCs, or whether IV administered MSCs can home and engraft into equine cutaneous 
wounds. 
The objectives of the this proof-of-principle pilot study were to (1) determine if subject 
horses developed adverse reactions during or for 6 weeks post-IV administration of >1.0 x 
108 fluorescently prepared allo-CB-MSCs, (2) describe the presence and patterns of homing 
and engraftment of fluorescently prepared allo-CB-MSCs in biopsies from wounded and 
non-wounded cutaneous tissue of the limb and thorax during healing, and (3) determine 
whether preliminary results suggest limb wounds have different patterns of CB-MSC 
homing and engraftment than thoracic wounds over time. 
4.2 Materials and Methods 
The experimental protocols (AUP #20140096) involving animals were approved by the 
University Animal Care Committee and Animal Research Ethics Board of the University of 
Saskatchewan.  
4.2.1 Overview of Study Design 
Standardized cutaneous wounds were created on the left lateral third metacarpus (MCIII) 
and left hemi-thorax. Twelve hours after wound creation, 1.02 x 108 live allogeneic CB-MSCs 
labeled with a fluorescent dye (PKH26) and transduced with an enhanced green fluorescent 
protein (eGFP) transgene were administered intravenously via the jugular vein. Red 
fluorescence of PKH26 allowed immediate identification of CB-MSCs in biopsy samples 
before green fluorescence of translated eGFP was consistently produced by viable CB-MSCs. 
Detection of red fluorescent signal of CB-MSCs in the early stages of wound healing was 
considered indicative of homing but not necessarily viability and engraftment, whereas 
detection of green and red fluorescent signal of CB-MSCs outside of the vasculature was 
considered indicative of homing, transendothelial migration and engraftment of viable CB-
MSCs. Biopsies were taken of wounds on the limbs and thoraces and of the corresponding 
contralateral non-wounded control sides on days 0, 1, 2, 7, 14, and 33 and evaluated by 
confocal microscopy for administered prepared CB-MSCs. Horses were monitored for 
adverse clinical reactions during injection and for the duration of the study period of 6 wk. 
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4.2.2  Recipient Animals 
Two sound 7-yr-old Thoroughbred mares with no history of injury to the forelimbs or 
thoracic wall that were healthy on physical exam with normal complete blood counts and 
serum chemistry were used. Horses were vaccinated (West Nile-Innovator+EWT®, Zoetis) 
and dewormed (Equimax®, Bimeda). Twelve hours prior to surgery, an intravenous 
catheter was aseptically placed in the left jugular vein and feed was restricted eight hours 
pre-operatively.   
4.2.3  Transducing and Labeling Trial 
Prior to commencement of the project, a trial sample of 1.0 x 106 CB-MSCs (eQcell 
Therapies Inc.; King City, Ontario, Canada) was acquired in order to determine logistics and 
timing of shipping and receiving, and to establish ideal transducing and labeling conditions. 
CB-MSCs were of the same source as the CB-MSCs used in the in vivo project. Optimal 
multiplicity of infection (MOI) and concentration of PKH26 was determined using the same 
AAV2-CMV-eGFP vector (AAV2.CMV.PI.eGFP.WPRE.bGH; Penn Vector Core, Gene Therapy 
Program, University of Pennsylvania) and PKH26 labeling kit (PKH26 Red Fluorescent Cell 
Linker; Sigma-Aldrich, Oakville, ON) as in the in vivo project. After transducing and labeling, 
CB-MSCs were cultured long term to determine fluorescent expression patterns of prepared 
CB-MSCs, establish label longevity, verify passage of fluorescence to daughter cells, and to 
confirm absence of cell toxicity. Using a similar protocol, we have previously shown that 
almost all testis stem cells exposed to AAV2 were successfully transduced with eGFP103 and 
stably expressed the eGFP transgene for several years in vivo104. 
4.2.4 Source and Transportation of CB-MSCs 
CB-MSCs originating from cord blood of five unrelated male donor foals were used (eQcell 
Therapies Inc.). This source of CB-MSCS has been previously demonstrated to produce a 
surface marker phenotype consistent with MSCs59 and were isolated using procedures as 
previously described66. At the time of shipment, the CB-MSCs had been cryopreserved once, 
passaged 4-5 times, and cultured for a total of 35-45 days. Twenty-four hours prior to 
injection, they were harvested using trypsin and disodium ethylenediaminetetraacetic acid 
(EDTA), washed in phosphate buffered saline (PBS), pooled to obtain a mixed population of 
donor cells, re-suspended in a serum-free commercial cell preservation medium 
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(HypoThermosol® FRS [HTS-FRS]; BioLife Solutions, Bothell WA) and cooled. The cooled 
CB-MSCs were shipped overnight to our laboratory in a reusable temperature controlled 
shipping container (Greenbox 2-8°C thermal management system, ThermoSafe ®, Arlington 
Heights, IL). A representative sample was taken and cell count and viability determined in 
duplicate and averaged using a haemocytometer counting chamber and trypan blue 
exclusion assay. A total of 4.16 x 108 cooled live CB-MSCs were received. 
4.2.5 Preparation of CB-MSCs 
Donor CB-MSCs were transduced in vitro with an eGFP transgene via an AAV2-CMV-eGFP 
vector as described in Section 4.2.3. CB-MSCs were exposed to the AAV2 at MOI of 1.0 x 
104 genome copies/cell. CB-MSCs were then incubated at 37ºC for 3 hr in vitro, washed 
twice by centrifugation at 500 x g for 5 min, and re-suspended in Dulbecco modified Eagle 
medium (DMEM; Mediatech, Manassas, VA).  
After transduction, CB-MSCs were labeled by incubation with PKH26 (Sigma-Aldrich) 
according the manufacturer’s instructions. Briefly, CB-MSCs were washed in DMEM, 
centrifuged at 400 x g for 5 min, and re-suspended in Diluent C. Immediately before 
staining, 2.0 x 10-5 molar of PKH26 dye was prepared using Diluent C, gently mixed with the 
CB-MSCs, and incubated at 25ºC for 6 min. Staining was stopped by the addition of fetal 
bovine serum (PAA Laboratories, Etobicoke, ON), and CB-MSCs were subsequently washed 
three times in DMEM. After the last wash, CB-MSCs were re-suspended in HTS-FRS for a 
total volume of 60 mL in a sterile syringe and kept cool until injection one hour later. After 
preparation, a representative sample of CB-MSCs was retained and cell count and viability 
was repeated using a haemocytometer counting chamber and trypan blue exclusion assay. 
Viability of CB-MSCs was 49% (2.04 x 108 CB-MSCs) and hence 1.02 x 108 CB-MSCs were 
administered to each horse. 
Additionally, a sample of prepared CB-MSCs was cultured into 6-well plates to serve as an in 
vitro reference for timing and pattern of fluorescence of prepared CB-MSCs. The 
supernatant from the last cell wash was also added to a cell culture of a sample of non-
prepared CB-MSCs to confirm no contamination of the supernatant with free PKH26. These 
cultures were maintained and observed for the duration of the study. 
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4.2.6 Wound Creation 
On day 0, horses were anaesthetized, maintained to effect on a guaifenesin, ketamine and 
xylazine intravenous drip (1 L 5% guaifenesin + 1000 mg ketamine + 500 mg xylazine) and 
placed in right lateral recumbency. After aseptic preparation, seven standardized full 
thickness excisional skin wounds were created using a scalpel on the left lateral MCIII and 
hemi-thorax at the region of the tenth costochondral junction of each horse (Figure 4.1). 
Wounds measured 0.5 cm x 2.0 cm in a horizontal orientation and orientated in a vertically 
stacked arrangement 2.0 cm apart. The wounds were covered during recovery from 
anaesthesia and then were left unbandaged to heal by second intention. Excised skin was 
retained for evaluation of baseline background fluorescence. Anti-inflammatories and 
antimicrobials were not administered at any time to avoid modification of inflammation. 
4.2.7  Prepared CB-MSC Administration and Monitoring 
On day 1, twelve hours after wound creation, the prepared CB-MSCs were injected via the 
indwelling catheter (4 mL/min over 15 min). During the injection, vital parameters were 
monitored for adverse clinical reactions (i.e., tachycardia, tachypnea, pyrexia, respiratory 
distress, colic, urticaria) every minute for the first 5 min followed by every 5 min until the 
suspension was administered. A physical exam was performed every 12 hr for the following 
36 hr then once daily for the following 7 days, followed by distance exams of general health 
and demeanour until the conclusion of the study 6 wk after injection. 
4.2.8 Biopsy Collection 
The two most proximal wounds on the limb and thorax were not biopsied and observed for 
healing characteristics in preparation for future studies. Horses were sedated and biopsies 
were taken of the remaining surgically created wounds of the limbs and thoraces and of the 
corresponding contralateral control sides on days 1, 2, 7, 14, and 33 in a distal to proximal 
sequence (Figure 4.1). Biopsied tissue was cooled and immediately processed and 
evaluated by confocal microscopy. 
4.2.9 Fluorescence Evaluation of Biopsies 
Confocal microscopy was used to determine normal background fluorescence of resected 
skin collected on day 0 and to detect fluorescent signal in biopsy tissue from administered  
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Figure 4.1: Basic schematic of wound creation and sequence of biopsy collection.  On day 0, seven 
wounds were created on the left forelimb and hemi-thorax of each horse measuring 0.5 cm x 2.0 cm and 
placed 2 cm apart in a vertical orientation.  Biopsies were collected on days (D) 1, 2, 7, 14, and 33 from the 
wound site and from the corresponding contralateral non-wounded site in a distal to proximal sequence.  The 
top two wounds were left to heal by second intention and observed for healing characteristics.  (OBS), 
observed. 
 
prepared CB-MSCs. One mm slices of fresh cooled biopsies were prepared and examined 
under a Leica epifluorescence microscope for red and green fluorescent signal using filter 
sets for GFP (excitation 450-490 nm/emission LP515 nm) and rhodamine (excitation 515-
560 nm/emission LP590 nm) with a 63 x oil objective and imaged with a Leica SP5 confocal 
microscope (Leica Microsystems; Watzlar, Germany) using the 488 nm line of an Argon 
laser (emission range of 500-535 nm for GFP) and the 543 nm line of a Helium Neon laser 
(emission range of 555-700 nm for PKH26). Biopsies from each collection period were 
evaluated by a blinded operator (E.K.). The operator subjectively evaluated the biopsies for 
presence of red and/or green signal and the intensity and distribution of the signal. 
Fluorescing cell-like structures were considered administered CB-MSCs if they had similar 
fluorescence patterns and were similar size to cultured CB-MSCs in our in vitro study. 
Fluorescent signal patterns were thoroughly described for each horse and then 
summarized. No difference in homing between the wound biopsies and the contralateral 
non-wounded biopsies was recorded as =, slightly more homing to wounds was recorded as 
+1, moderately more homing was recorded as +2, and markedly more homing was recorded 
as +3. Presence of red fluorescence was recorded as R and presence of green fluorescence 
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was recorded as G. Biopsies in which signal was absent or rarely detected was further 
recorded as none or rare. 
4.3 Results 
4.3.1 Adverse Reactions 
Neither of the horses developed adverse clinical reactions during injection of the prepared 
CB-MSCs and all evaluated vital parameters remained within normal limits. One horse had 
symptoms of mild colic (abdominal pain) prior to injection of the CB-MSCs that was 
attributed to anaesthesia and because her vital signs remained normal the CB-MSCs were 
administered. After administration of the CB-MSCs, she responded well to minimal 
intervention (oral fluids, oral mineral oil, sedation [xylazine, 150 mg IV]) and did not 
experience any more colic symptoms throughout the duration of the study period. There 
was mild edema of the tissue adjacent to the wounds in both horses for a few days following 
wound creation and biopsy collection; however, lameness was not apparent at the walk and 
intervention was not needed. Both horses remained comfortable and did not develop any 
adverse reactions throughout the remainder of the study period.   
4.3.2 Confocal Microscopy Observations 
4.3.2.1 In vitro culture 
On all days, CB-MSCs measured approximately 15-20 μm in length and 10-15 μm in width. 
On day 1, prepared CB-MSCs had dots of predominantly red fluorescence measuring on 
average 2 μm uniformly distributed throughout the cell on phospholipid membranes and 
very weak green signal was also detected as dots (Figure 4.2a). On day 7, dots of red 
fluorescence remained uniformly distributed and weak green signal was detected as small 
dots <1 μm in diameter and/or generalized green fluorescence of the cytoplasm with low 
amounts of colocalization of green and red signal (Figure 4.2b). On days 14 and 33, the 
distribution of green signal remained similar to day 7 but more vibrant and readily 
detectable (Figure 4.2c, d). Green signal was most intense on day 33 (Figure 4.2d). On day 
14 and 33, amount of colocalization of green and red signal varied between individual cells 
but was typically low to moderate. 
29 
 
4.3.2.2 In vivo tissue biopsies (Table 4.1): 
Day 0:  
Collagen fibres demonstrated normal green and red auto-fluorescence consistently in limb 
and thoracic biopsies of both horses. There were no cell-like structures that had similar 
fluorescent patterns to cultured prepared CB-MSCs (Figure 4.3).   
Day 1:  
Red and green signal was typically colocalized and detected in all biopsies except in the 
non-wounded thoracic biopsy of horse 1. Signal was typically highly concentrated in the 
vasculature and both horses had slightly more signal in the wounded limb and thoracic 
biopsies (Figure 4.4a, c).   
Day 2:  
Colocalized red and green signal was detected in all biopsies. In biopsies of limb wounds of 
both horses, slightly more signal was detected compared to non-wounded limb biopsies. 
There was no difference in amount of signal or pattern of distribution in wounded and non-
wounded thoracic biopsies of both horses. In all biopsies, signal was detected within the 
vasculature in clusters, but also was located along the endothelium of the vessels, possibly 
consistent with endothelial adhesion of CB-MSCs (Figure 4.5c, d). In wounded and non-
wounded limb biopsies of horse 1, cell-like structures measuring ~8-10 μm were 
occasionally detected outside of the vasculature in the interstitium (Figure 4.5b). 
Day 7:  
Red and green colocalized signal was detected in all biopsy sites of both horses. In horse 1, 
there was no difference in amount of detected signal from wounded or non-wounded 
biopsies of the limb or thorax. Furthermore, in both wounded and non-wounded limb and 
thoracic sites, signal was detected primarily within and along the endothelium of the 
vasculature (Figure 4.6c, d). In wounded and non-wounded limb biopsies, occasional cell-
like structures were detected in the interstitium measuring 8-10 μm (Figure 4.6a) and 
larger cell-like structures measuring 15-20 μm were detected within the vasculature along 
the endothelium (Figure 4.6b). In horse 2, there was no difference in detected signal in 
wounded and non-wounded limb biopsies. Occasional cell-like structures measuring 12-20 
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μm were detected within the vasculature of both wounded and non-wounded limb sites 
(Figure 4.6a). In the thorax, there was one area in the wounded site that contained several 
cell-like structures measuring 8-11 μm in the interstitium, but otherwise there was no 
difference in detected signal between wounded and non-wounded biopsies. Cell-like 
structures were occasionally detected within the vasculature of both wounded and non-
wounded thoracic sites.  
Day 14:  
In both horses, there was no difference in pattern of distribution of red or green signal, or 
intensity of fluorescence in limb or thoracic wounded and non-wounded biopsies. Red and 
green signal was typically colocalized and located both within and out of the vasculature. In 
addition, signal that formed clumps of ~5 μm was often found along the endothelial surface 
of vessels, just adjacent to the vasculature or in the interstitium (Figure 4.7a). A single cell-
like structure measuring 15 μm was detected in the interstitium of the non-wounded limb 
of horse 2 and wounded thorax of horse 1 (Figure 4.7b, c). 
Day 33:  
On day 33, red and green signal was more readily apparent in limb and thoracic wounds of 
both horses (Figure 4.8a, c). More specifically, signal was colocalized and predominately 
detected as cell-like structures between 10-20 μm. These cell-like structures were found in 
clusters and larger cell-like structures measuring 15-20 μm were often elongated. Both 
larger and smaller cell-like structures appeared to be integrated into the interstitium. In the 
non-wounded limb and thoracic biopsies, cell-like structures were rarely detected, 
rounded, located often within the vasculature, and measured between 5-12 μm, smaller 





Table 4.1: Summary of Labelled CB-MSC Fluorescent Signal Colour and Homing to Wounds 
 Day 1 Day 2 Day 7 Day 14 Day 33 
Subject Biopsy Site Color Homing Color Homing Color Homing Color Homing Color Homing 









 Limb Non-Wounded R, G R, G R, G R, G R, G 









 Thorax Non-Wounded none R, G R, G R, G R, G 









 Limb Non-Wounded R, G R, G R, G R, G R, G 









 Thorax Non-Wounded R, G R, G R, G R, G R, G 
Homing was considered present if more red and/or green signal was detected in biopsies of wounds compared to the corresponding contralateral non-
wounded site at the same time period, regardless of whether signal was detected intravascular or extravascular. Abbreviations: Color - (R), presence of 





Figure 4.2: Representative confocal microscopy images of in vitro cultured prepared CB-MSCs. (a) Day 1, 
(b) day 7, (c) day 14, and (d) day 33. All images were captured using the same settings except for day 7 (b), 
which was captured with a higher sensitivity setting for green to demonstrate subtle green signal. CB-MSCs 
are clumped in day 1 (a) and day 33 (d). In all images, individual CB-MSCs measured between 781 15-20 μm 
lengthwise and 10-15 μm widthwise. On day 1 (a), many red fluorescent dots were uniformly distributed on 
phospholipid membranes with very weak green signal. On day 7 (b), CB-MSCs maintained red signal but also 
began to produce stronger green signal as dots or generalized throughout the cytoplasm. On day 14 (c) and 
day 33 (d), CB-MSCs remained similar to day 7 (b) but had brighter green signal of the cytoplasm and 
organelles. On day 33 (d) green signal was more intense than previous days. Colocalization of red and green 





Figure 4.3: Representative confocal microscopy images of normal skin of the limb and thorax before 
surgical creation of wounds. a) Horse 2, thorax, b) horse 2, thorax, c) horse 1, thorax, and d) horse 1, limb. In 
both the limb and thorax, collagen fibers demonstrated normal green and red auto-fluorescence. No cell-like 




Figure 4.4:  Representative confocal microscopy images of biopsies of limb and thoracic wounds and 
contralateral non-wounded skin on day 1.  a) Wounded limb, b) non-wounded limb, c) wounded thorax, 
and d) non-wounded thorax. Images were selected from either horse based on best representation of patterns 
typical fluorescent signal patterns of both horses. Images have been selectively enhanced for purposes of 
demonstrating signal variation. There was slightly more homing to wounded limbs (a) and wounded thoraces 






Figure 4.5:  Representative confocal microscopy images of biopsies of limb and thoracic wounds and 
contralateral non-wounded skin on day 2.  a) Wounded limb, b) non-wounded limb, c) wounded thorax, 
and d) non-wounded thorax. Images were selected from either horse based on best representation of patterns 
typical fluorescent signal patterns of both 803 horses. Images have been selectively enhanced for purposes of 
demonstrating signal variation. There was slightly more homing to limb wounds (a) than the non-wounded 
limb site (b). There was no difference in homing between the thoracic wounds (c) and non-wounded thoracic 
sites (d). Signal was red and green and located within the vasculature and occasionally along the endothelium 
(d) of both wounded and non-wounded biopsies. Cell-like structures measuring 8-10 um with colocalization of 
red and green signal were occasionally detected adjacent to the vasculature in wounded and non-wounded 




Figure 4.6:  Representative confocal microscopy images of biopsies of limb and thoracic wounds and 
contralateral non-wounded skin on day 7.  a) Wounded limb, b) non-wounded limb, c) wounded thorax, 
and d) non-wounded thorax. Images were selected from either horse based on best representation of patterns 
typical fluorescent signal patterns of both horses. Images have been selectively enhanced for purposes of 
demonstrating signal variation. Red and green signal was detected in all wounded and non-wounded biopsies. 
There was no difference in homing to wounds in either horse except for an area of the wounded thorax in 
horse 2 that had several cell-like structures. Signal was located within the vasculature along the endothelium 
in both horses (c, d) and cell-like structures consistent with in vitro CBMSCs were occasionally detected 




Figure 4.7:  Representative confocal microscopy images of biopsies of limb and thoracic wounds and 
contralateral non-wounded skin on day 14.  a) Wounded limb, b) non-wounded limb, c) wounded thorax, 
and d) non-wounded thorax. Images were selected from either horse based on best representation of patterns 
typical fluorescent signal patterns of both horses. Images have been selectively enhanced for purposes of 
demonstrating signal variation. In both horses, there was no difference in amount of distribution of red or 
green signal. Signal was often colocalized in small clumps and located within or just adjacent to the 
vasculature (a). Single cell-like structures consistent with in vitro CB-MSCs were detected in the interstitium 
of the non-wounded limb of horse 1 (arrow, b) and wounded thorax of horse 2 (arrow, c). Background auto-




Figure 4.8:  Representative confocal microscopy images of biopsies of limb and thoracic wounds and 
contralateral non-wounded skin on day 33.  a) Wounded limb, b) non-wounded limb, c) wounded thorax, 
and d) non-wounded thorax. Images were selected from either horse based on best representation of patterns 
typical fluorescent signal patterns of both horses. Images have been selectively enhanced for purposes of 
demonstrating signal variation. In both horses, homing was marked in both limb and thoracic wounds and 
was characterized by cell-like structures consistent with in vitro CB-MSCs that appeared to be well integrated 
into the interstitium (arrows, a, c). In contrast, cell-like structures were only rarely detected in the non-
wounded side and were rounded, located primarily in the vasculature, and were smaller than those typically 






To the authors’ knowledge, 1.02 x 108 is the largest amount of allo-MSCs that have been 
administered intravenously to horses, and we did not detect any clinical adverse reactions 
directly attributable to allo-MSC therapy. This is encouraging because despite evidence that 
equine MSCs have immunosuppressive properties14,59,60,62,74,105–107, and intravenously 
administered MSCs are well tolerated64,71,95,102, complications and reactions secondary to 
allo-MSC therapy and IV MSC administration can occur. Previously reported immune 
responses in horses to allo-MSCs include allo-antibody production101,102,108, increased 
circulating lymphocyte population64,71, wheal formation and local lymphocyte response 
after intradermal administration98,101,109, and increased lameness and nucleated cell counts 
after intrasynovial injection110. Regardless, in these studies all local reactions were self-
limiting and no horses developed systemic adverse reactions. Reported complications 
related to intravascular MSC administration in other species include fatal pulmonary 
embolism in mice21, cerebral embolism in rats90, pulmonary parenchymal edema and 
haemorrhage in dogs91, and portal vein thrombosis in humans111. Despite these reports, 
complications are typically not encountered and IV administration of MSCs appears to be 
well-tolerated in most species112,113. However, laboratory animals used in IV MSC studies 
are often administered upwards of 1.6 x 104 MSCs per gram16,92. Clearly, administering 
similar amounts of MSCs per gram to a horse would be cost prohibitive. While the ideal 
dose of MSCs for a beneficial effect is unknown, neither positive clinical effects nor adverse 
reactions may be seen unless higher doses are used; therefore, we felt it important to 
evaluate the effects of a larger dose of IV MSCs than had been previously administered. 
Although we did not evaluate peripheral blood or tissues, the lack of clinical complications 
following injection of twice the amount of the past largest recorded dose of allo-MSCs71 
suggests it may be clinically safe to do so, but trials with larger numbers of subject horses 
must be repeated to assert clinical safety. 
Cell-like structures detected in vivo were occasionally smaller than measured CB-MSCs in 
vitro. This was expected as confocal imaging wound have captured CB-MSCs in transverse, 
oblique, or sagittal planes as they interacted three-dimensionally with the surrounding 




culture dish. Also, detected cell-like structures in vivo had different colocalization patterns 
of red and green signal compared to in vitro CB-MSCs. In vivo, red and green signal was 
predominantly colocalized whereas in vitro, red and green signal was typically separate 
although colocalization of signal was occasionally seen in some cells. The difference in 
signal colocalization of in vitro and in vivo CB-MSCs is likely due to differences of 
interactions of the cells with their environment; more specifically, signal was more 
commonly colocalized in in vivo cells because of three-dimensional interaction with the 
local niche and ligand binding, stimulating increased packaging and transportation of eGFP 
in PKH26 labeled organelles compared to in vitro CB-MSCs114,115. Regardless, there was still 
striking similarity between cultured CB-MSCs and in vivo cell-like structures. Hence, we 
considered cell-like structures that had red and green signal similarly distributed as 
cultured CB-MSCS to be injected fluorescently prepared CB-MSCs, irrespective of 
colocalization of signal. 
MSC homing is defined as “the arrest of a MSC within the vasculature followed by 
transmigration across the endothelium”86 and MSC engraftment is defined as integration 
and survival of MSCs in the target tissue after transendothelial migration87. Inflammation is 
a very important factor for influencing both homing and engraftment rates. Although not as 
well understood as leukocyte homing, MSCs can home to target tissues actively by rolling, 
adhering and migrating through vasculature activated by the inflammatory cascade, and 
passively by migrating through the endothelium after becoming entrapped in non-activated 
capillaries86. Recently developed techniques to increase MSC homing have integrated 
principles of inflammation to either “prime” MSCs to increase efficiency of transendothelial 
migration or modify the target tissue to be more receptive to MSC engraftment86,87,116,117. 
For example, preconditioning MSCs in a hypoxic environment will cause upregulation of 
CXCR4, a chemokine receptor important for homing, on MSC surface membranes and 
improve homing rates86,87,116,117. Ischemic post-conditioning of the target tissue has also 
been shown to improve homing and engraftment rates by decreasing reperfusion injury 
and creating a less hostile environment for engrafting MSCs87. Determining the exact 
mechanism of CB-MSC homing and engraftment and the relationship of the CB-MSCs with 




agreed upon that inflammation plays a role in both active and passive mechanisms of MSC 
homing and engraftment. Therefore, we considered homing synonymous with engraftment 
and that homing to have occurred when red and/or green signal was detected more 
frequently in biopsies of wounds compared to non-wounded sites at each time period. 
Although only two horses were used in this pilot project and conclusions must be drawn 
cautiously, our results suggest CB-MSC homing and engraftment indeed occurred and 
temporal and regional inflammation likely influenced detection patterns. 
Except for thoracic wounds on day 2, CB-MSCs preferentially homed to wounds in both 
horses on days 1 and 2 during the acute inflammation phase, and on day 33 during the early 
remodelling phase, where homing and engraftment was most obvious (Table 4.1; Figure 
4.8). Furthermore, the engrafted CB-MSCs in the wounded sites on day 33 were elongated 
and occasionally found in clusters, possibly representative of differentiation and/or 
proliferation (Figure 4.8). This is in contrast to homing and engraftment patterns of 
intravenously administered MSCs in mice where homing is typically greatest during the 
acute inflammatory phase followed by a rapid decrease or absence of engrafted MSCs as 
inflammation resolves17,82,83, suggesting that the majority of engrafted MSCs are eventually 
rejected. Why we saw a different homing pattern is unknown, but we can speculate based 
on findings from other research. In a rat knee osteoarthritis model, MSCs administered 
intra-articularly persisted in arthritic knees more than twice as long than in normal knees 
and began to proliferate118. The investigators hypothesized that a local inflammatory 
environment is favourable for MSC engraftment and supports MSC viability and 
proliferation. In addition, other researchers have shown that successfully engrafted MSCs 
can recruit more locally engrafted MSCs119 as well as local and distant endogenous MSCs120. 
Based on these studies, it is possible on day 33 that ongoing and persistent chronic 
inflammation in the wounds produced an inflammatory environment that was favourable 
for CB-MSC engraftment and proliferation, and the engrafted CB-MSCs then recruited other 
locally engrafted CB-MSCs to the site as well as began to proliferate. In contrast, CB-MSCs 
were detected only rarely if at all in biopsies of the contralateral non-wounded site because 
local intermittent acute inflammation created during previous biopsy collections had 




lack of chronic inflammatory stimulus. Although dual Ki-67/eGFP immunohistochemistry 
was not performed to confirm differentiation and proliferation, we cannot disregard CB-
MSC proliferation as a possible reason for increased CB-MSC detection on day 33. 
Regardless, the marked homing of CB-MSCs to the wounded sites and not the control sites 
suggests that CB-MSCs successfully homed and engrafted to the wounded site and possibly 
began to proliferate while continuing to recruit other engrafted CB-MSCs. 
Because the original intents of this project was not to determine the relationship of the CB-
MSCs with the vasculature, imaging of vessels was inconsistent and we cannot state 
whether the relationship of the CB-MSCs with the vasculature was consistent between 
biopsy sites or throughout time. However, in hindsight, the relationship of the CB-MSCs 
with the vasculature and apparent engraftment seemed to be related to the phases of 
healing and are important to note in our observations. During the inflammatory phase, CB-
MSCs were detected in close relationship with the vessels, either intravascularly along the 
endothelium, or adjacent to the vessels within the interstitium (Figures 4.4, 4.5), but during 
the early remodelling phase CB-MSCs were typically detected engrafted in the interstitium 
and not immediately adjacent to the vessels (Figure 4.8). These preliminary observations 
are consistent with the extravasation phase and interstitial migration phase of systemic 
MSC homing and engraftment86 although further studies are needed to validate this 
observation.  
Differences between degree of CB-MSC homing in the limb and thoracic biopsies were only 
apparent on day 2; more specifically, mild homing was apparent in limb wounds but there 
were no differences in homing in thoracic wounds (Table 4.1; Figure 4.4). This was 
unexpected as wounds on the body of horses have a more pronounced acute inflammatory 
response than limb wounds4,24, which theoretically could cause greater MSC homing and 
recruitment. However, we did not observe this phenomenon. It is possible, that 
inflammation created at the control hemi-thorax sites from biopsy collection the day before 
(day 1) created an inflammatory response that caused CB-MSCs to home to the 
contralateral non-wounded biopsy site, negating any difference in CB-MSC homing to the 
thoracic wound sites on day 2. Because limb wounds have a more mild inflammatory 




apparent in the limbs. It is also possible that limbs have a unique feature that increases 
their ability to recruit MSCs compared to other areas of the body. It is widely accepted that 
equine limb wounds have a different temporal cytokine profile that affects wound healing 
compared to other areas of the body4,24, and so it possible that limb wounds may also have 
unique cytokine profiles or regional anatomical features that are favourable to MSC 
recruitment, such as increased hypoxia-inducible factors, endothelial adhesions receptors, 
and signalling pathways86,87,116. However, because we did not detect any other differences 
of homing between limb and thoracic wounds at any of the other time points this theory is 
less likely and purely speculative although further studies investigating this theory would 
be interesting. 
After intravenous MSC administration, the majority of MSCs are entrapped in the 
pulmonary vasculature, which is known as the “first pass effect”79. Despite this, positive 
effects of intravenous MSC therapy are still seen due to a rapid release of 
immunomodulatory factors from entrapped MSCs that systemically influence healing79. In 
addition, even low engraftment rates improve wound healing through secretion of factors 
that recruit endogenous MSCs and promote angiogenesis16,120. Even though most of the 
administered CB-MSCs likely became entrapped in the lungs, we still detected CB-MSCs in 
the biopsies, indicating that CB-MSCs can home to and engraft in cutaneous wounds after 
passing through the lung vasculature in horses. As far as we are aware, we are the first 
group to detect CB-MSCs in equine cutaneous wounds after intravenous administration.   
There are some limitations to the present study. First, this was a proof-of-principle pilot 
project with only two treatment horses. However, except for day 7 where horse 2 had 
increased homing to wounds and horse 1 did not, both horses had similar homing patterns 
for all time periods, and we feel our results are accurate and collectively our observations 
can be viewed as visual evidence of MSC homing. Second, the total fluorescence of the 
biopsied tissues was not quantified by software or graded. However, software evaluation 
can introduce further bias as subjective evaluation is required to determine background 
versus cellular fluorescence, while a grading system would have had limited application 
with only two horses. Third, the donor and the recipient horses were not cross-matched so 




matching haplotypes. However, domestic horses have upwards of 29 different haplotypes 
121, and the CB-MSCs were pooled from five different individual donors, therefore it is very 
unlikely that all the donors and the recipients had matching haplotypes. Fourth, tissues and 
blood samples were not collected to determine if there were immunologic or physiologic 
reactions. However, because the horses did not experience clinically detectable adverse 
reactions, humoral and cellular immune responses are likely inconsequential. And finally, 
biopsy collection at the control sites created inflammation that may have influenced homing 
to the sequential control sites, although the amount of inflammation was far less than the 
wounded sites. This could have been controlled for by including more horses and collecting 
a biopsy from each horse only once at a single time period; however, this would be cost 
prohibitive and the benefit of using the same animal as its own control would be lost. 
4.5  Conclusions 
In the present proof-of-principle pilot project, we are able to report that after intravenous 
administration of the largest recorded dose of CB-MSCs (1) our study horses did not have 
any clinical adverse effects, (2) CB-MSCs preferentially homed and engrafted to wounds 
during the acute and early remodelling phases of cutaneous wound healing, and (3) there 
was no difference in homing between limb and thoracic wounds except on day 2 where CB-
MSCs homed to limb wounds, but not thoracic wounds. The lack of adverse effects and 
demonstration of visual validation of homing and engraftment after intravenous 
administration is new to the equine literature and it is important information for further 
MSC research in horses. Moreover, these results further promote the horse as a good animal 
model for studying keloid MSC therapy in people. Although preliminary, the initial results 







5.  IDENTIFICATION OF mRNA OF THE INFLAMMATION-ASSOCIATED PROTEINS 
CXCL8, CXCR2, CXCL10, CXCR3 AND β-ARRESTIN-2 IN EQUINE WOUNDED CUTANEOUS 
TISSUE: A PRELIMINARY STUDY 
 
Transition Statement: 
This chapter presents the findings of the gene expression of the inflammation-associated 
proteins CXCL8/CXCR2, CXCL10/CXCR3 and βarr2 in equine limb and thoracic wound tissue 
and describes their expression throughout wound healing.  The intents of this project was to 
determine the feasibility of processing wound tissue biopsy tissue for mRNA multiplex assay as 
well as confirm that the primers of these proteins would have good detection in equine 
cutaneous tissue before commencing with the main project.  
 
This study confirmed that using primers of the aforementioned inflammation-associated 
proteins were well detected using mRNA multiplex assay, and initial observations suggest that 
there are differences in expression of CXCL8/CXCR2 and βarr2 between limb and thoracic 
wounds.  This study contributes important preliminary information to the equine literature 
about the expression of these proteins in wound tissue that has not been described before, and 
variations in their expression provides further insights into the variation of limb and thoracic 
wound healing in horses. 
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5.1 Introduction 
Cutaneous wounds are common in horses and often lead to prolonged and complicated 
healing.  Wound healing is a complex process finely orchestrated by cytokines and growth 
factors that influence all phases of healing and deviations in the amount or order of 
cytokine release contributes to abnormal healing26.  Limb wounds heal slower and have a 
propensity to develop exuberant granulation tissue (EGT) compared to body 
wounds6,42,44,45,122.  Past studies have identified that chronic low-grade inflammation in limb 
wounds causes dysregulation of cytokine profiles, promoting EGT formation6–8,42,44,45,122,123.  
Similarly, humans also develop hypertrophic scars and keloids when cytokine release is 
dysregulated38,124,125. The development of fibroproliferative disorders in both horses and 
humans can severely affect quality of life and is a major financial burden38.  EGT formation 
on the limbs of horses shares similar qualities with fibroproliferative disorders in people, 
including a similar contraction to epithelialization ratio, heritability of the disorder, 
dysregulated cytokine profiles, and haphazard collagen deposition38,46.  Interestingly, 
horses and humans are the only species that spontaneously develop these fibroproliferative 
disorders; thus, horses may be good models for studying aberrant wound healing in 
humans38.  Consequently, recording cytokine profiles during wound healing in the horse is 
important to identify possible time points for intervention to avoid aberrant healing and for 
establishing its usefulness as a model of wound healing in humans.   
Chemokines are small proteins that initiate chemotaxis of leukocytes to the site of 
inflammation through binding of G-protein coupled receptors (GPCRs).  Chemokines are 
classified based on their conserved cysteine (C) residues of which there are 4 groups: CXC, 
CC, C, and CX3C.  The CXC group is further divided into subtypes according to the glutamate-




CXC chemokines are strong neutrophil attractants and promote angiogenesis, and are 
likewise considered pro-inflammatory mediators.  In contrast, ELR negative CXC 
chemokines are poor neutrophil activators but strong lymphocyte and monocyte 
attractants and are angiostatic; hence, they are considered inflammation-resolving 
mediators126,127.  
CXC ligand 8 (CXCL8) is an ELR positive CXC chemokine that is released by damaged cells at 
the site of injury.  As such, it is a potent chemoattractant for neutrophils and triggers 
angiogenesis. The GPCR for CXCL8 is CXC receptor 2 (CXCR2) and is primarily expressed on 
the surface of neutrophils and endothelial cells126,127.  The CXCL8/CXCR2 axis is associated 
with acute inflammation and human wound-healing models have identified a direct 
temporal and spatial relationship between expression of CXCL8 and infiltration of 
neutrophils into the wound128,129.  The expression of CXCR2 is tightly regulated to prevent 
excessive inflammation.  Within five minutes of binding with CXCL8, CXCR2 internalizes 
within neutrophils, then is later recycled to the surface130.  This process is regulated 
primarily through β-arrestin-2 (βarr2), a ubiquitously expressed intracellular protein that 
negatively regulates inflammation through internalization of GPCRs, including CXCR2131.  
βarr2 null mice have improved wound healing secondary to increased expression of CXCR2 
by neutrophils which allows continuous binding with CXCL8 and therefore more 
pronounced neutrophil chemotaxis to the wound, initiating the inflammatory cascade132.  
However, βarr2 null mice also have accelerated tumour growth through continued 
CXCL8/CXCR2 binding on endothelial cells, promoting angiogenesis133.  This emphasizes 
the importance of tight regulation of cytokine production.  
In contrast to the effects of CXCL8, CXC ligand 10 (CXCL10) is an ELR negative CXC 
chemokine and is released during the proliferative and maturation phases of wound 
healing.  It is angiostatic and it attracts lymphocytes and monocytes, which are involved in 
resolving inflammation and promoting scar formation126,134.   The GPCR for CXCL10 is CXC 
receptor 3 (CXCR3) which is expressed on the surface of T-lymphocytes, monocytes, 




The importance of the resolution phase of wound healing is well demonstrated in CXCR3 
null murine models135.  These mice have an adequate acute inflammatory response but 
delayed re-epithelialization and hyperkeratotic scar formation characterized by haphazard 
fibroplasia and decreased scar strength.  Similar to the relationship of CXCL8 and CXCR2, 
the CXCL10/CXCR3 axis is also tightly regulated although βarr2 plays a less pivotal role.  
This tight regulation is especially important to prevent excessive inflammation secondary 
to T-lymphocyte activation - leukocytes that are also involved in autoimmune diseases.  
Shortly after ligand binding, CXCR3 becomes internalized by βarr2, but then is degraded 
rather than recycled as with CXCR2.  More CXCR3 must then be translated from mRNA, 
delaying expression of CXCR3 and preventing further T-lymphocyte activation.  In addition 
to βarr2 mediated internalization, the responsiveness of CXCR3 can also be decreased 
through binding of intracellular regulatory Gαi2 subunits to CXCR3, another checkpoint to 
prevent excessive inflammation by T-lymphocytes136. 
In normal circumstances, the local cytokine environment triggers appropriate phases of 
acute inflammation, inflammation resolution, and maturation of the wound.  However, if 
appropriate cytokine release is interrupted at any of these phases, delayed healing and 
dystrophic scarring can occur26.  
To the authors’ knowledge, gene expression of these inflammation-associated proteins have 
not been identified in equine cutaneous tissue.  Identification of these proteins is an 
important first step to understanding the roles they play in equine wound healing.  
Variations in temporal profiles may further explain why limb wounds heal differently than 
body wounds in horses.  In addition, documentation of temporal cytokine patterns is 
important to add to our understanding of equine wound healing and strengthens the 
usefulness of the horse as an animal model for studying fibroproliferative disorders in 
humans.  Furthermore, understanding the role of these proteins in wound healing may lead 
to novel ancillary treatments including CXC chemokine/GPCR axis manipulation137,138. 
Our primary objective was to determine if mRNA of CXCL8, CXCR2, CXCL10, CXCR3 and 
βarr2 can be detected in convenience-sampled frozen equine wounded cutaneous tissue at 




technology.  Our secondary objective was to graph the mean fluorescent intensity (MFI) of 
the mRNA of these proteins over time for limb and thoracic wounds to determine if there 
are temporal or site variations to guide future investigations. 
5.2 Materials and Methods 
The mRNA expression levels of CXCL8, CXCR2, CXCL10, CXCR3 and βarr2 were measured 
using the QuantiGene Plex assay method (Thermo Fisher Scientific, Santa Clara, CA, USA) on 
frozen equine tissue previously collected from another cutaneous wound healing study.  
Use of animals in the project was approved by University Animal Care Committee (UACC) 
and Animal Research Ethics Board (AREB) of the University of Saskatchewan.  In that study, 
seven standardized surgical excisional cutaneous wounds were created under general 
anaesthesia on the left lateral metacarpus and left thorax of two seven-year-old 
Thoroughbred mares on day 0.  Resected skin was retained for reference as normal non-
traumatized tissue.  Both horses received 1.02x108 equine umbilical cord blood multipotent 
mesenchymal stromal cells (MSCs) (eQcell Therapies Inc., King City, Ontario, Canada) 
injected into the left jugular vein twelve hours after wound creation.  Biopsies were 
collected from the wounds sequentially starting from the most distal and ventral site on the 
metacarpus and thorax, respectively, on days 1, 2, 7, 14 and 33.  All biopsy tissue was 
immediately snap-frozen and stored at -80°C.  mRNA was isolated from frozen tissue 
samples using a QuantiGene sample processing kit for fresh tissue (Thermo Fisher 
Scientific).  The assay was performed in duplicate using equine specific primers according 
to the manufacturer’s protocol.  Samples were analyzed using Luminex Bio-Plex 200 
instrumentation (Bio-Rad Laboratories Ltd., Mississauga, Ontario).  Results were 
normalized using expression of hypoxanthine-guanine phosphoribosyltransferase (HPRT).  
Data for both horses was averaged and graphed over time.  Results are expressed as MFI for 
the mRNA of each protein. 
5.3 Results and Discussion 
Multiplex mRNA assay technology detected mRNA of all target proteins at all of the time 
points (Figure 5.1), meeting our primary objective.  To our knowledge, this is the first time 
gene expression of these inflammation-associated proteins have been detected in equine 




method was simple and effective and eliminated the need to isolate mRNA for each protein 
from each tissue biopsy, which increased processing speed and decreased chance for error.  
Multiplex mRNA assay technology is capable of identifying up to 36 different assays in a 
single sample and has been proven to be a time-efficient and cost-effective alternative to 
real-time PCR139,140.  Multiplex mRNA assay technology is a promising tool for wound 
studies as many cytokines and growth factors involved in healing can quickly be profiled 
and their complex relationships compared. 
The MFI of gene expression of each of the proteins was graphed over time (Figure 5.1).  
Although the initial data is preliminary, it is interesting and warrants further thought and 
investigation.  The CXCL8/CXCR2 axis demonstrated a pattern of expression that was 
distinct for the limb and thorax.  Specifically, thoracic wounds had a monophasic pattern of 
expression with a peak MFI for both CXCL8 and CXCR2 on day 7, whereas limb wounds had 
a biphasic pattern of expression with peak expression during the resolution phase of wound 
healing on day 33 for both CXCL8 and CXCR2 (Figures 5.1a, b).  Interestingly, the expression 
pattern of CXCR2 was similar to expression of βarr2 (Figure 5.1e).  After internalizing its 
respective GPCR, βarr2 is downregulated transcriptionally and translationally minutes to 
hours after ligand binding; as such, βarr2 expression patterns reflect its respective GPCR141 
so it would be expected that βarr2 expression would mirror that of CXCR2.  The expression 
patterns of CXCR2 and βarr2 in the limb and thorax are similar to hemoglobin levels in a 
study by Celeste et al42.  In that study, hemoglobin was measured over 4 weeks at various 
time points using near infrared spectroscopy and was considered an indicator of blood flow 
and angiogenesis.  Hemoglobin levels were biphasic in the limb with peak levels during 
early and late stages of healing, whereas body wounds had peak hemoglobin levels on day 7 
of healing.  A major stimulus for angiogenesis is hypoxia through the action of 
CXCL8/CXCR2 binding on endothelial cells26, and Celeste et al42 hypothesized that early and 
late hemoglobin levels in the limbs were reflective of angiogenesis and vasodilation in 




Figure 5.1.  Gene expression of CXCL8 (A), CXCR2 (B), CXCL10 (C), CXCR3 (D) and βarr2 (E) measured 
in mean fluorescent intensity (MFI) in wounded equine cutaneous tissue over time (days).  Thoracic 
wounds demonstrate monophasic expression patterns with peak MFI on day 7 in all proteins except CXCR3.  
Limb wounds demonstrate biphasic expression patterns with peak MFIs in acute and resolution phases of 
wound healing in all proteins except CXCR3.  Changes in CXCR3 expression patterns were minimal except for 
peak MFI on day 1 in the limb.   
 
endothelial cells as well as neutrophils, it is possible that the biphasic CXCL8/CXCR2/βarr2 
gene expression patterns that we detected are reflective of early and late angiogenesis as 
well as chronic low-grade inflammation. 
CXCL10 mRNA was also expressed biphasically in limb wounds and monophasically in the 
thorax, although the magnitude of peak MFI is less than the CXCL8/CXCR2 axis (Figure 
5.1c).  In addition, this pattern was not seen in expression of CXCR3 (Figure 5.1d).  Other 
than a peak MFI on day 1 of limb wounds, CXCR3 gene expression remained near baseline.  
CXCR3 is very tightly regulated through several check-points including βarr2 mediated 




inflammation136.  It is possible slight variations of expression of the CXCL10/CXCR3 axis 
between limb and thoracic wounds may not have been apparent in our study due to tight 
regulation.   
Overall, our preliminary results suggest that differences in gene expression patterns of 
CXCL8/CXCR2, and βarr2 between the limb and thorax are controlled locally rather than 
systemically as there are regional anatomic variations in expression.  However, 
CXCL10/CXCR3 expression did not seem to vary greatly between limb and thoracic wounds.  
We are currently determining whether these patterns are significantly different between 
limb and thoracic wounds in a larger study. 
It is imperative to note that these preliminary results must be interpreted cautiously as 
there are only two horses involved.  Furthermore, mRNA levels reflect transcription of 
genes and do not necessarily represent translation of mRNA into functional proteins.  In 
addition, the biopsies were collected from subject horses that received intravenous MSCs 
and MSCs have known immunomodulatory effects142 and thus the detected mRNA may not 
be representative of normal gene expression for limb and thoracic wounds.  Nevertheless, 
this is the first time that the mRNA of these inflammation-associated proteins have been 
detected in equine cutaneous tissue and we have confirmed that they can be detected at 
several time points throughout wound healing.  Our results provide an important starting 
point for further investigations into the characterization of the effects of these proteins in 
equine wound healing.   
5.4 Conclusions 
In conclusion, we were successful in identifying gene expression of CXCL8/CXCR2, 
CXCL10/CXCR3 and βarr2 at all time points during healing using multiplex mRNA assay 
technology.  Our preliminary results suggest that the temporal expression patterns for 
CXCL8/CXCR2 and βarr2 are different for limb and thoracic wounds in horses and are likely 
controlled locally as there are regional anatomical differences.  These variations may 
further explain why limb wounds are more prone to developing EGT than body wounds. In 
addition, this study further supports the notion that horses may be suitable animal models 




6.  THE MACROSCOPIC, HISTOLOGIC, AND IMMUNOMODULATORY RESPONSE OF 
EXPERIMENTALLY CREATED LIMB WOUNDS FOLLOWING INTRAVENOUS ALLOGENEIC 
CORD BLOOD-DERIVED MULTIPOTENT MESENCHYMAL STROMAL CELL THERAPY IN 
HORSES 
Transition Statement: 
This chapter presents the results of allo-CB-MSC IV therapy on equine limb wounds with 
specific regard to macroscopic wound closure, histologic response, and gene expression of 
wound associated cytokines, using techniques and methods previously verified in Chapters 4 
and 5.  
 
Results determined that minor transitory adverse responses may occur following 
administration, and treated horses had improved macroscopic wound closure characteristics.  
Furthermore, allo-CB-MSC IV therapy may have a generally anti-inflammatory effect as 
determined by the measured cytokine profiles.  These results provide new important 
information to the equine literature in regards to wound healing, and that ancillary MSC 
therapy may improve wound healing characteristics and provide a better final outcome, hence 
improving the long-term welfare of the affected horse. 
 
6.1 Introduction 
Traumatic cutaneous wounds occur frequently in horses and often develop complications, 
particularly if the wound is on the limb.  Compared to wounds on the body, limb wounds 
have less contraction and heal primarily through epithelialization, resulting in a repair that 
lacks hair and sebaceous glands and is cosmetically and functionally inferior and prone to 
reinjury24.  Furthermore, limb wounds are more likely to develop exuberant granulation 
tissue (EGT), a fibroproliferative disorder similar to keloid formation in humans24,38.  
Anatomically, the limb lacks a panniculus carnosus muscle to assist wound contraction and 
high mobility of the distal limb puts repeated tension on the wound that slows 
contraction24,38.  Furthermore, limb wounds are more likely to become contaminated and 
colonized with bacteria24,38,40 whereas body wounds seem to be highly resistant to biofilm 




compared to body wounds24,43, leading to hypoxia and upregulation of transforming growth 
factor-beta (TGFβ)1, a potent stimulator of fibrosis and granulation tissue44,45.  
Furthermore, compared to horses, pony wounds heal faster regardless of their location and 
rarely develop EGT, even though ponies and horses are the same species4,24, suggesting that 
horses may have inherent deficient healing characteristics. 
Regenerative therapies, such as multipotent mesenchymal stromal cells (MSCs), have been 
investigated in recent years as ancillary treatments to improve wound healing in several 
species, including horses19,20.  Intravenous (IV) administration of MSCs has been shown to 
accelerate and improve cutaneous healing in laboratory animal wound models15,84,143.  It is 
believed that improved quality and acceleration of healing occurs by immunomodulation 
locally following MSC migration and engraftment at the site16,17,84 as well as systemically in 
response to entrapment of MSCs in the lungs known as the “first-pass-effect”16,79.  
Allogeneic (allo)-MSCs are promising as they can be collected non-invasively, be 
characterized, expanded and stored long-term for future use, and be administered shortly 
after injury during the acute inflammatory phase when MSC therapy may be the most 
effective18,62,78.  In the equine literature, several studies have been performed to determine 
the recipients’ responses to IV MSC administration12,64,71,89,94–96, but none have determined 
whether IV MSC therapy alters cutaneous wound healing or influences the local immune 
response.  
The effective cell dose of IV MSCs required to influence wound healing in horses is 
unknown.  Currently, the highest dose administered IV to an equid is 5 x 107 cells per 
animal71 with no reported clinical adverse responses.  In studies with laboratory mice, 
typically 1 x 106 cells are administered per mouse16, equivalent to 33 x 106 cells per 
kilogram.  Administering the same dose to a horse would be cost prohibitive and technically 
very challenging, but a clinically measurable response is more likely to be seen with a total 
IV dose beyond what is currently being administered to horses, provided there are no 
adverse reactions. 
The primary objectives of this study were to determine whether 1.51 – 2.46 x 108 allo- cord 




creation of limb wounds would (1) cause a clinically detectable adverse response, (2) 
influence epithelialization and contraction rates and hence wound closure, and (3) 
influence histologic healing characteristics.  A secondary objective was to record gene 
expression levels of proinflammatory (chemokine [C-X-C motif] ligand 8 (CXCL8), tumour 
necrosis factor-alpha [TNFα]), anti-inflammatory (interleukin [IL]-4, IL-10), inflammation 
resolving (CXCL10, interferon-gamma [INFγ]), and fibrosis related (TGFβ1, TGFβ2, TGFβ3) 
cytokines over time and determine whether IV allo-CB-MSC therapy would significantly 
alter their pattern of expression.  Our hypotheses were that IV allo-CB-MSC therapy would 
not cause a clinically adverse response, would accelerate the rate of wound closure, and 
would improve histologic healing characteristics. 
6.2 Materials and Methods 
6.2.1 Overview of Study Design 
Twelve horses were randomized into treatment and control groups for a total of six horses 
in each group.  To accommodate constraints of facility housing and anaesthesia personnel, 
and to allow time for expansion and shipment of allo-CB-MSCs, horses were further divided 
into three subgroups consisting of two treatment and two control horses (Subgroups 1, 2, 
and 3). Standardized cutaneous wounds were surgically created on the lateral left forelimb 
of all four horses in each subgroup on a single day.  Twelve hours after wound creation, 
each treatment horse was administered half of the CB-MSCs procured from a third party via 
the jugular vein after quantifying viability and re-suspending the CB-MSCs in a cell 
preservation medium. At the same time, control horses received a placebo injection of 50% 
diluted cell preservation medium only (Figure 6.1). Full thickness biopsies were taken of 
the wounds on days 0, 1, 2, 7, 14, and 28.  The biopsies were graded histologically for 
inflammation and repair and mean fold change (MFC) of messenger ribonucleic acid 
(mRNA) expression levels of proinflammatory, anti-inflammatory, inflammation resolving, 
profibrotic, and antifibrotic cytokines were measured using multiplex mRNA assays. The 
proximal most wound was never biopsied and was photographed on days 7, 14, 21, and 28 
(Figure 6.2).  Planimetric analysis of the digital images was used to determine the wound 




Figure 6.1: Basic schematic of division of horses into treatment and control subgroups and total 
number of allo-CB-MSCs administered.  A total of twelve horses were randomly placed into a treatment and 
control group and then further divided into three subgroups.  Following shipment of cells, a total cell count 
and assessment for viability using trypan blue staining and enumeration with a haemocytometer was 
performed.  The total remaining live cells were then evenly divided and administered IV to the treatment 
horses and the control horses were administered a placebo IV injection of 50% diluted HTS-FRS. 
 
(Figure 6.3).  The day the wound was considered healed was recorded, which was when the 
epithelial borders met at the center of the wound.  Horses were monitored for adverse 
clinical reactions during injection and for 4 weeks following administration. 
6.2.2 Recipient Animals 
Twelve female adult horses of Quarter Horse descent with no physical evidence of past 
injury to the limbs were acquired.  Horses ranged in age from 3-16 years (mean +/- SD, 8.3 
+/- 3.5 years) and weight from 425-547 kg (mean +/- SD, 486 +/- 39.2 kg).  All horses were 
healthy on physical exam and had normal complete blood counts and serum chemistry at 




dewormed (Equimax®, Bimeda).  An intravenous catheter was placed aseptically in the left 
jugular vein twelve hours prior to surgery and feed was withheld for eight hours prior to 
induction of anaesthesia.  As the created wounds were objectively small and discomfort 
associated with the wounds would be relatively minor, no anti-inflammatory analgesics or 
antibiotics were administered throughout the study as to not alter the inflammatory 
response. 
6.2.3 Wound Creation 
On day 0, horses were anesthetised as previously described (see Chapter 4).  After clipping 
and prepping the area aseptically, six full-thickness excisional skin wounds measuring 0.5 x 
1.5 cm in a horizontal orientation were created on the lateral aspect of the left metacarpus 
in a vertically stacked arrangement 2.0 cm apart.  Similarly, wounds were created on the 
left lateral thorax at the site of the 10th costochondral junction for purposes of studying 
wound healing characteristics of thoracic wounds in a separate study.  Results of healing of 
the thoracic wounds are not reported in this manuscript.  A portion of excised skin was 
placed in formalin for histologic evaluation and the remainder was snap frozen and stored 
at -80°C for later multiplex cytokine mRNA assays for baseline analysis of aforementioned 
cytokines (Figure 6.2).  A bandage was placed on the limb to prevent blunt trauma during 
recovery from anaesthesia and removed afterwards to prevent influencing granulation 
tissue formation24.  Wounds were left to heal by second intention with no intervention such 
as cleansing or bandaging.  Horses were monitored daily for lameness and excessive 
swelling throughout the course of the study. 
6.2.4  Source of CB-MSCs, Administration, and Monitoring 
CB-MSCs originating from five unrelated male donor foals (eQcell Therapies Inc.; Kingston, 
Ontario, Canada) were characterized, prepared, processed, and shipped as previously 
described (see Chapter 4)59,66. Upon arrival of the shipment, viability was determined using 
a haemocytometer counting chamber and trypan blue exclusion assay and cells re-




Figure 6.2: Basic schematic of wound creation and sequence of biopsy collection.  On day 0, six wounds 
were created on the left forelimb of each horse measuring 0.5 cm x 1.5 cm and placed 2 cm apart in a vertical 
orientation.  On days 1, 2, 7, 14, and 28 a biopsy was collected from both the dorsal and palmar aspect of the 
wound in a distal to proximal sequence.  The dorsal biopsy was submitted for histology and the palmar biopsy 
was snap frozen for later multiplex mRNA assays.  The top wound was left to heal by second intention imaged 
on days 7, 14, and 28 and assessed by planimetric analysis for rate of wound closure. 
 
[HTS-FRS]; BioLife Solutions, Bothell WA) to a total volume of 60 mLs, immediately placed 
on ice and cooled to approximately 4°C. Twelve hours after wound creation, suspended CB-
MSCs were administered to treatment horses, and control horses were administered a 
placebo injection of 60 mLs 50% diluted HTS-FRS, over 15 minutes (4 mL/minute) via the 
indwelling catheter.  Vital parameters were measured prior to injection and then every 
minute for the first five minutes followed by every five minutes until administration of the 
suspension was complete.  If a horse demonstrated signs of an adverse reaction 
(tachycardia, tachypnea, hyperthermia, colic, urticaria, fasciculations, agitation/anxiety), 
administration was suspended until symptoms abated and continued at a slower rate until 
the administration was complete.  In subgroup 1, a total of 5.04 x 108 CB-MSCs with 60.0% 
viability were received and a total of 1.51 x 108 viable CB-MSCs were administered to each 




received and a total of 2.15 x 108 viable CB-MSCs were administered to each treatment 
horse.  In subgroup 3, 5.96 x 108 CB-MSCs with 82.6% viability were received and a total of 
2.46 x 108 viable CB-MSCs were administered to each treatment horse (Table 6.1; Figure 
6.1).  A physical exam was performed every 12 hours for the first seven days followed by a 
distance exam daily until the conclusion of the study at 28 days. 
Table 6.1 Summary of Total CB-MSCs Received and Administered per Horse in Each 
Subgroup following Viability Assessment 
 Total Cells Received Viability Total Cells Administered per horse 
Subgroup 1 5.04 x 108 60.0% 1.51 x 108 
Subgroup 2 6.51 x 108 66.0% 2.15 x 108 
Subgroup 3 5.96 x 108 82.6% 2.46 x 108 
 
6.2.5 Biopsy Collection 
Biopsies were collected during the per acute (day 1) and acute (day 2) inflammatory phase, 
during the mid (day 7) and late (day 14) proliferative phase, and the early (day 28) 
remodelling phase. At each time point, treatment and control horses were sedated (0.01 
mg/kg detomidine + 0.01 mg/kg butorphanol, IV) and biopsies collected from one site at a 
time in a distal to proximal sequence after subcutaneous infiltration of local anaesthetic 
(lidocaine 2%). More specifically, on day 1, biopsies were collected from the most distal 
wound; on day 2, from the second most distal wound; on day 7 the third most distal wound; 
on day 14 the third most proximal wound; and on day 28 the second most proximal wound.  
Two biopsies were collected from each of the dorsal and palmar margins of the wound 
using a 6 mm punch biopsy instrument that included approximately half skin and half 
wounded tissue.  The dorsal biopsy was preserved in formalin for histopathology and the 
palmar portion snap frozen and stored at -80°C for later multiplex cytokine mRNA assays 




6.2.6 Wound Closure Analysis 
Photographs were taken of the proximal most wound with a metric ruler adjacent to the 
wound for calibration on days 7, 14, 21, and 28, and the day of its complete wound closure 
was recorded.  Wound closure was considered complete when epithelialization covered the 
granulation tissue bed and met at the center of the wound.  Images were randomized and 
the wound areas were measured in triplicate, calibrated to the ruler in the image by a 
blinded evaluator (S.M.).  Using planimetric analysis, the percentage of closure by 
contraction and epithelialization was determined compared to the original wound size 
(Image-Pro®, Media Cybernetics, Inc., Rockville, MD., USA) (Figure 6.3).  The following 
formulas were used: 
x Percent epithelialization  
(Area of non-haired wound on day(x)mm2 – Area of open granulation tissue on 
day(x)mm2) / Area of original created wound on day(0)mm2 x 100 
 
x Percent contraction 
Area of non-haired wound on day(x)mm2 / Area of original created wound on day(0)mm2 
x 100 
6.2.7 Histologic Analysis 
Biopsies were randomized by treatment and time and graded by a blinded board certified 
veterinary pathologist (B.W.).  A grading scale modelled after other wound grading scales 
(Table 6.2)20,144 was created based on progression of repair and inflammation on days 1, 2, 
7, 14, and 28.  More specifically, the total repair score was the sum of epithelialization, 
collagen and vascularization scores, and a separate inflammation score was given for the 
state of vascular and cellular inflammation.  As healing progressed, theoretically the repair 






Figure 6.3:  Representative diagram of measured areas of wound to determine proportion of wound 
closure by contraction and epithelialization by using calibrated planimetric analysis.  A) Representative 
area of the original created wound (day 0) in relation to the current (day x) measured wound.  B) Shaded area 
represents area of open granulation tissue.  C) Epithelialization was determined by measuring the total area of 
non-haired wound area and then subtracting open granulation tissue previously measured in B.  D) Total 
contraction was determined by subtracting both the previously measured open granulation tissue in B and 
epithelialized tissue in C from the original created wound size in A (day 0). 
 
6.2.8  Multiplex Cytokine mRNA Assays 
Messenger RNA of proinflammatory (CXCL8, TNFα), anti-inflammatory (IL-4, IL-10), 
inflammation resolving (CXCL10, IFNγ), profibrotic (TGFβ1, TGFβ2) and antifibrotic 
(TGFβ3) cytokines were isolated from the frozen biopsies using a QuantiGene Plex assay 
processing kit according to the manufacturer’s protocol (Thermo Fisher Scientific, Santa 
Clara, CA, USA) for each of the biopsy collection days.  The assay was performed in duplicate 
using equine specific primers including CXCL10 that was previously developed in a 
preliminary study (See Chapter 5)35. Samples were analyzed using Bioluminex processer 
(Bio-Rad Laboratories Ltd, Mississauga, Ontario) and results normalized to hypoxanthine 
guanine phosphoribosyltransferase and expressed as combined MFC for the 







Table 6.2: Histologic Repair and Inflammation Grading Scale 
Repair Grade Inflammation Grade 
Score Epithelialization Score Collagen Score Vascularization Score Inflammatory Response 









1 Activated endothelium 1 Hemorrhage – no inflammatory cells 






2 Macrophage dominated 






4 Keratinization 4 Return to normal dermal collagen 4 
Return to normal 
vascular 4 Neutrophil dominated 





6.2.9 Statistical Analysis 
Collected data was entered into a commercial spreadsheet (Microsoft Excel, Version 2016).  
Statistical analysis was performed with a commercial software package (Stata 15.1; 
Statacorp, College Station, Texas, USA).  Data from all treatment and control subgroups 
were combined into a single treatment group and single control group as there was 
minimal subgroup variation.  The outcome variable of days to complete healing was 
determined to have a normal distribution using the Shapiro-Wilk test and then treatment 
and control groups were compared using the two-sample t-test with significance set at P ≤ 
0.05.  Histologic healing and inflammation scores for each day were evaluated using 
Wilcoxon-Rank Sum with significance set at P ≤ 0.05.  The MFC of cytokines, area of non-
haired portion of the wounds, and percentage of contraction and epithelialization were 
analyzed with a generalized estimating equations (GEE) model utilizing Gaussian data 
distribution, exchangeable correlation structure, and robust standard errors.  Variables for 
consideration in the GEE model were the treatment group (treatment vs. control) and the 
day of measurement.  Interaction effects for treatment group and day were evaluated and 
where significant interaction existed an overall treatment effect is not reported. A limit of P 
≤ 0.2 for overall treatment effect of all measured days was set as the threshold to further 
consider effect of treatment at each individual day.  Pairwise comparison was performed for 
individual days and a P value of ≤ 0.05 (adjusted for multiple comparisons over days) was 
considered significant.  Outcomes from GEE are reported as linear predicted contrast (95% 
confidence interval) between the treatment and control groups. Differences in measures 
were estimated with the contrast of predicted margins. 
6.3 Results 
6.3.1  CB-MSC Administration and Monitoring 
Three horses (50%) in the treatment group (two in subgroup 2, and one in subgroup 3) and 
one horse (17%) in the control group (subgroup 3) experienced transient infusion 
reactions (Table 6.3).  All horses remained normothermic.  In the treatment group, horses 




tachypneic (40-64 breaths per minute), were restless, and had mild colic symptoms (lip 
Table 6.3 Summary of Adverse Clinical Responses Following IV allo-CB-MSC Administration 
Horse Group Subgroup Symptoms Summary Response to Decreased Infusion Rate 
8 Treatment 2 
Reaction following 28 mLs 
of infusion. 
Normothermic, mild 
tachycardia (48 bpm), 
moderate tachypnea (64 
bpm), mild restlessness 
Discontinued infusion for 
five minutes. Vital 
parameters returned to 
normal.  Continued 
infusion.  No alterations in 
vital parameters. 
12 Treatment 2 
Normothermic, mild 
tachycardia (48 bpm), 
moderate tachypnea (42 
bpm), mild restlessness, 
mild colic symptoms (lip 
curling) 
Continued infusion at a 
slower rate.  Symptoms 
resolved within fifteen 
minutes. 
7 Treatment 3 
Reaction following 28 mLs 
of infusion.  
Normothermic, moderate 
tachycardia (60 bpm), 




(stretching, looking at 
flank) 
Discontinued infusion for 
ten minutes.  Heart rate 
and respiratory rate 
returned to normal.  
Continued infusion slowly.  
Colic symptoms resolved 
15 minutes after infusion 
completed. 
11 Control 3 
Reaction following 12 mLs 
of infusion.  
Normothermic, marked 
tachycardia (72 bpm), 




Discontinued infusion for 
fifteen minutes.  Muscle 
fasciculations resolved.  
Continued infusion slowly.  
Heart rate fluctuate 
between 48 and 60 bpm 
during infusion.  
Restlessness resolved 
shortly after completely 
infusion. 
 
curling, stretching, flank watching). The control horse had marked tachycardia (72 beats 
per minutes) and moderate tachypnea (40 breaths per minute) as well as marked 




horses, administration was suspended until symptoms abated (5-15 minutes) and then 
continued at a slower rate.  All horses returned to normal vital parameters shortly after 
completion of administration and had normal physical exams for the remainder of the 
study. 
6.3.1 Wound Closure Analysis 
One of the treatment horses in subgroup 3 sustained a large degloving injury on the lateral 
aspect of the right neck on day 22.  Because inflammation created by the neck wound may 
have influenced healing of the experimental limb wounds and confound results, the data 
collected from her was subsequently eliminated from analysis for the remainder of the 
study. 
In the control group, wounds had complete closure on day 27 ± 3 and the treatment group 
had complete closure on day 26 ± 4.  There was no significant difference between treatment 
and control groups based on the number of days recorded for complete  
 
Table 6.4 Time to Limb Wound Closure following IV allo-CB-MSC administration 
Horse Group Days to Closure 
Mean Days 
to Closure ± SD P value 
2 Treatment N/A 
26 ± 4 
0.702 
3 Treatment 22 
6 Treatment 21 
7 Treatment 26 
8 Treatment 30 
12 Treatment 30 
1 Control 28 
27 ± 3 
4 Control 28 
5 Control 28 
9 Control 30 
10 Control 24 





healing to occur (two sample t-test, 95% CI, -4.10 to 5.83; P = 0.702) (Table 6.4). Non-
haired wound size became larger than the original created wound size, known as the lag 
phase10, in both the treatment and control groups on day 7, and continued to get larger in 
the control group on day 14, but became smaller than the original wound size in the 
treatment group on day 14 (Figure 6.4).  An overall treatment effect over all days was seen 
for non-haired wound size, where treated horses had smaller wounds, and hence 
potentially a smaller dermal scar, than control horses (GEE, 95% CI, -23.9 to 3.51; P = 
0.145), but there was no significant interaction at individual days (Table 6.5; Figure 6.4).  
The rates of epithelialization and contraction were compared between groups overtime.  
CB-MSC treatment had an overall treatment effect on epithelialization over all days (GEE, 
95% CI, -0.214 to -0.023; P = 0.015) with a significant treatment effect on day 14 (GEE, 95% 
CI -0.280 to -0.0189; P = 0.0173) (Table 6.5; Figure 6.5).  CB-MSC therapy influenced an 
overall treatment effect on contraction over all days (GEE, 95% CI, -0.0462 to 0.313; P = 
0.146) characterized by a trend for a less pronounced lag phase in the treatment group than 
the control group, although no significant interaction was identified at individual days 
(Table 6.5; Figure 6.6).  By day 28, the treatment group had healed with approximately 75% 
contraction and 25% epithelialization (Figure 6.7b) whereas the control group had 
approximately 60% contraction and 40% epithelialization (Figure 6.7a).  
6.3.3 Histologic Analysis 
Histologic repair and inflammation scores between each group were virtually identical with 
very little variation at each of the days; thus, statistical analysis was not performed.  In both 
treatment and control groups, the repair score increased and the inflammation score 
decreased throughout time as anticipated.  The following repair and inflammation scores 
are reported sequentially biopsies collected on days 1, 2, 7, 14, and 28.  In the treatment 
group, average repair scores were 3.00, 4.00, 8.12, 11.67, and 15.00; likewise, the control 
group had average repair scores of 3.00, 4.00, 8.00, 11.67, and 15.00.  The treatment group 
had average inflammation scores of 5.00, 5.00, 4.00, 3.00, and 1.00, and similarly the control 
group had average inflammation scores of 5.00, 5.00, 4.00, 2.67, and 1.00. Descriptive data 






Table 6.5 Rate of Limb Wound Closure by Epithelialization and Contraction following IV allo-CB-MSC Administration 
 Wound Area (mm2) Epithelialization (%) Contraction (%) 
Day Contrast 95% CI P Value (Adjusted) Contrast 95% CI 
P Value 
(Adjusted) Contrast 95% CI 
P Value 
(Adjusted) 
7 -8.12 -34.9 to 18.7 0.909 -0.121 
-0.419 to 
0.176 0.774 0.0974 
-0.224 to 
0.419 0.909 
14 -19.5 -43.1 to 4.02 0.147 -0.140 
-0.280 to -
0.0189 0.0173* 0.260 
-0.0536 to 
0.574 0.147 
21 -6.03 -26.8 to 14.7 0.921 -0.0537 
-0.282 to 
0.175 0.962 0.0804 
-0.196 to 
0.357 0.921 
28 -7.09 -23.6 to 9.41 0.782 -0.151 
-0.342 to 







Figure 6.4: Total non-haired wound area of limb wounds following IV CB-MSC administration.  There 
was an overall decrease in total non-haired wound area over all days but no significant treatment effect at 
individual days.  Both treatment and control wounds had an increase in non-haired wound area during the lag 
phase but was less pronounced in the treatment group. 
 
 
Figure 6.5: Total area of epithelialization (%) contributing to wound closure of limb wounds following 
IV CB-MSC administration.  There was an overall decrease in total epithelialization over all days with 
significant treatment effect on day 14 (P = 0.0173). 






Figure 6.6: Total area of contraction (%) contributing to wound closure of limb wounds following IV 
CB-MSC administration.  There was an overall increase in total contraction over all days with no significant 















Figure 6.7: Total area of contraction (%) and epithelialization (%) contributing to wound closure of treatment and control limb wounds 
following IV CB-MSC administration.  There was an overall increase in total contraction and epithelialization over all days in the treatment group (A).  
The lag phase was less pronounced in the treatment group and wound closure was healed with approximately 75% contraction and 25% 







Table 6.6 Histologic Repair and Inflammatory Scores of Limb Wounds following IV allo-CB-MSC Administration in Horses 
 Histologic Repair Score Histologic Inflammation Score 
Group Horse Day 1 Day 2 Day 7 Day 14 Day 28 Day 1 Day 2 Day 7 Day 14 Day 28 
Treatment 
2 3 4 8 12 N/A 5 5 4 3 N/A 
3 3 4 9 12 15 5 5 4 3 1 
6 3 4 8 12 15 5 5 4 3 1 
7 3 4 8 11 15 5 5 4 3 1 
8 3 4 8 11 15 5 5 4 3 1 
12 3 4 8 12 15 5 5 4 3 1 
Control 
1 3 4 8 13 15 5 5 4 1 1 
4 3 4 8 11 15 5 5 4 4 1 
5 3 4 8 11 15 5 5 4 3 1 
9 3 4 8 12 15 5 5 4 3 1 
10 3 4 8 12 15 5 5 4 3 1 





6.3.4 Multiplex Cytokine mRNA Assays 
IV allo-CB-MSC administration had an overall treatment effect over all days on 
proinflammatory cytokines (GEE, 95% CI, -3.81 to -0.172; P = 0.032) with a significant 
individual treatment effect on day 2 (GEE, 95% CI, -10.4 to -2.26; P = 0.0003) (Figure 6.8).  
An overall treatment effect over all days was seen where anti-inflammatory mediators were 
lower (GEE 95% CI, -0.330 to -0.0251; P = 0.022), but there was no significant treatment 
effect at individual days (Figure 6.9). An overall treatment effect over all days was seen 
where inflammation resolving mediators were lower (GEE margins 95% CI, -0.558 to -
0.0229; P = 0.033), but there was no significant treatment effect at individual days (Figure 
6.10).  An overall treatment effect over all days was seen where profibrotic mediators were 
lower (GEE margins 95% CI, -0.431 to 0.0863; P = 0.191), but there was no significant 
interaction at individual days (Figure 6.11).  There was no treatment effect overall or at 
individual days for antifibrotic mediators (Figure 6.12).  In summary, there was an overall 
treatment effect over all days that lowered proinflammatory, anti-inflammatory, 
inflammation resolving, and profibrotic mediators, although there were not significant 
differences at individual days except for proinflammatory mediators on day 2.  There were 
no significant differences at individual days or overall treatment effect between the 






Figure 6.8: Mean fold change (MFC) of mRNA expression of proinflammatory cytokines over time 
following IV allo-CB-MSC therapy.  There was an overall treatment effect over all days characterized by 
decreased expression of proinflammatory cytokines with an individual significant treatment effect on day 2 (P 
= 0.032).  
(*) = significant difference 
 
 
Figure 6.9: Mean fold change (MFC) of mRNA expression of anti-inflammatory cytokines over time 
following IV allo-CB-MSC therapy.  There was an overall treatment effect over all days characterized by 





Figure 6.10: Mean fold change (MFC) of mRNA expression of inflammation resolving cytokines over 
time following IV allo-CB-MSC therapy.  There was an overall treatment effect over all days characterized 
by decreased expression of inflammation resolving cytokines with no significant treatment effect on 
individual days.   
 
 
Figure 6.11: Mean fold change (MFC) of mRNA expression of profibrotic cytokines over time following 
IV allo-CB-MSC therapy.  There was an overall treatment effect over all days characterized by decreased 





Figure 6.12: Mean fold change (MFC) of mRNA expression of antifibrotic cytokines over time following 
IV allo-CB-MSC therapy.  There was neither overall treatment effect over all days nor significant treatment 





Table 6.7 Summary of mRNA Cytokine Expression of Limb Wounds Following IV allo-CB-MSC Administration 
 Proinflammatory Anti-inflammatory Inflammation Resolving Profibrotic Antifibrotic 
 Contrast 95% CI P Value Contrast 95% CI P Value Contrast 
95% 






























Contrast 95% CI 
P Value 






(Adjusted) Contrast 95% CI 
P Value 
(Adjusted) Contrast 95% CI 
P Value 
(Adjusted) 





























0.808 -0.440 -1.36 to 0.481 0.755 -0.234 
-1.25 to 













0.296 -0.592 -1.37 to 0.182 0.238 -0.322 
-1.16 to 













0.312 -0.488 -1.12 to 0.147 0.232 -0.403 
-1.13 to 
0.323 0.607 -0.467 
-1.39 to 
0.460 0.708 
















0.897 -0.696 -2.14 to 0.748 0.747 
















1.00 0.0399 -2.18 to 2.26 1.00 
(*) – indicates threshold for overall treatment effect over all days (P≤0.2). 




6.4  Discussion 
This study utilized an IV dose range of 1.51 – 2.46 x 108 viable CB-MSCs administered to 
horses, which is the higher than the previously highest dose that our team had 
administered in the pilot project (see Chapter 4).  This dose of cells was determined by the 
maximum amount of CB-MSCs that the supplier was able to provide as resources and 
facilities allowed. As far as the authors are aware, this is the highest dose administered to a 
horse experimentally via any route.  Contrary to our hypothesis, 50% of the horses in the 
treatment group experienced a clinically adverse reaction.  Interestingly, one control horse 
(17%) also had a clinically adverse response to the placebo suspension (Table 6.3).  
Previous studies by other researchers examining IV MSC administration in horses did not 
detect any clinically adverse reactions, although the amounts administered were relatively 
small12,71,89,94–96.  In our previous studies, the treatment horses received twice the 
previously highest reported IV dose71, and did not have any clinically measurable responses 
(see Chapter 4).  However, potential adverse reactions were still considered possible in the 
treatment group secondary to major histocompatibility complex (MHC) reaction12,70,71 and 
pulmonary vascular injury21,91.  A clinical response was not anticipated in the control group 
as the placebo injection contained only chilled diluted HTS-FRS cellular suspension 
medium.  Possible reasons for the responses to the administered perfusate in both 
treatment and control groups are 1) thermic response to a chilled intravenous solution, 2) 
immunological response to the cells and/or a substance in the suspension medium, and 3) 
physiologic response to concentrated electrolytes within the perfusate.  Although possible, 
administration of relatively small volumes of a chilled solution is unlikely to cause systemic 
reactions.  Saline chilled to 4°C is commonly administered to hyperthermic human 
individuals at approximately 1 mL/kg/min for 30 minutes without complications145, far 
more than the 0.0089 mL/kg/min of the HTS-FRS that our horses were administered.  The 
make up of the HTS-FRS contains several electrolytes at elevated concentrations that may 
explain the clinical effects that were seen.  HTS-FRS is a cell preservation medium designed 
to maintain cell viability of chilled or frozen mammalian cells.  The composition of HTS-FRS 
is not public, but is similar to the concentration of intracellular solutes71.  An earlier public 
version of an intracellular-like HTS-maintenance solution intended as a blood substitute 




mEq/kg/hr147, or 3.75 mEq/min for the average 450 kg horse.  Assuming HTS-FRS has a 
similar concentration of potassium as the original maintenance solution, administration of 
60 mLs of 50% diluted HTS-FRS over fifteen minutes would be equivalent to 0.085 
mEq/min for the averaged sized horse, well within the safe rate.  Similarly, Williams et al71 
determined that a 10 mL bolus of undiluted HTS-FRS, alone or containing 5 x 107 
mismatched CB-MSCs, did not induce clinically detectable adverse reactions when 
administered to ponies.  In our study, live cells were not filtered from the delivered solution 
to avoid further cell stress and cell death. Lysed cells could potentially release a significant 
amount of intracellular potassium that may cause transient symptoms of hyperkalemia in 
the treatment group, but obviously would not have altered the cell-free HTS-FRS placebo 
suspension administered to the control horses.  Some individuals may be particularly 
sensitive to alterations in circulating potassium concentrations, and/or the patented HTS-
FRS may contain a concentration of potassium higher than the original maintenance 
solution. Furthermore, it is possible that the HTS-FRS contains a preservative that could 
cause an immunological response in some individuals.  Regardless, the symptoms 
experienced were transient and mild, although one should consider administering HTS-FRS 
at an even slower rate to potentially avoid reactions.   
Intravenous administration of CB-MSCs did not accelerate time to wound closure or 
improve the histologic repair score, contrary to our hypotheses (Table 6.6).  However, CB-
MSC therapy did have a treatment effect over all days where the treated horses had more 
contraction and less epithelialization, characterized by significantly less epithelialization on 
day 14 (Table 6.5; Figures 6.4, 6.5, 6.6).  Furthermore, although not significant, there was a 
trend in the treatment group for a less pronounced lag-phase during contraction in the first 
two weeks, and the treated horses wounds healed with approximately 75% contraction and 
25% epithelialization compared to the control group that had 60% and 40% contraction 
and epithelialization, respectively (Figures 6.5, 6.7). In all equine wounds, during the lag 
phase the wound edges will retract and the wound will initially get larger and then decrease 
in size as myofibroblasts begin to infiltrate the wound to contract the dermal edges 
centripetally to the center of the wound, allowing for a smaller area requiring repair 




studies3,6,42,45.  A cutaneous wound healed primarily with epithelialization is more fragile 
and weaker than normal skin, and on horse limbs only achieves 60% of its original strength 
of normal skin37.  Furthermore, it has a poorer cosmetic and functional outcome as it 
consists mainly of acellular collagen and is devoid of components such as hair follicles and 
sebum and apocrine glands, whereas a wound that has closed mostly with contraction has 
an intact dermis10.  Although ultimately IV CB-MSC therapy did not improve the time to 
wound closure or histologic quality of healing, a positive healing response was still 
appreciated because the smaller visible dermal scars from more contraction and less 
epithelialization would have a potentially better cosmetic and functional repair than 
untreated cohorts. 
A secondary objective of this study was to determine whether IV CB-MSC therapy would 
significantly alter the mRNA expression of several inflammatory mediators.  There was a 
treatment effect over all time points with less proinflammatory, anti-inflammatory, 
inflammation resolving, and profibrotic cytokine mRNA expression, although no 
significance at individual days was detected other than significantly less expression of 
proinflammatory mediators on day 2 (Table 6.7; Figures 6.8, 6.9, 6.10, 6.11).  To the 
authors’ knowledge, no comparable wound cytokine analysis studies have been performed 
in horses following IV MSC therapy.  In laboratory species, IV MSC therapy modulates the 
proinflammatory response systemically similar to what we measured in our horses.  In a 
bladder obstruction model using rats, IV MSCs significantly lowered expression of 
proinflammatory (TNFα) and profibrotic (TGFβ1) genes and had decreased collagen 
deposition in the detrusor muscle, improving bladder function148.  Also, IV MSCs decreased 
expression of proinflammatory (TNFα) genes and improved histologic scores in a rat colitis 
model80.  In a burn wound healing model using rats, IV MSCs decreased expression of 
proinflammatory (TNFα) proteins and had improved healing time and histologic 
appearance84.  However, all three of these laboratory animal models also saw an increase in 
anti-inflammatory mediators, contrary to the decrease that we measured in our horses.  
Furthermore, in an equine in vivo study where CB-MSCs were injected locally in the dermis 
surrounding limb wounds, the profibrotic mediator TGFβ1 was significantly increased 




the rat bladder obstruction model148 as well as our horses.  MSCs exert their influence 
through immunomodulation both locally and systemically16.  After IV infusion, MSCs 
become entrapped in the lungs, but still suppress inflammation through secretion of anti-
inflammatory cytokines which are absorbed by the pulmonary vasculature and are 
distributed systemically, having effects at local sites of injury16,79.  MSCs also modify the 
immune response through “licensing” - where activated MSCs secrete anti-inflammatory 
cytokines after exposure to proinflammatory cytokines117.  This process appears to be 
somewhat dose dependent to initial exposure of TNFα and/or INFγ.  Although speculative, 
it is possible that our treated horses had a lessened initial systemic proinflammatory 
response after MSC lung entrapment, which then likewise decreased a reciprocated 
licensed release of endogenous anti-inflammatory and inflammation resolving cytokines at 
the wound site. This cytokine profile may have promoted the trends for increased 
contraction and decreased epithelialization in the treatment group, although investigating 
this relationship was beyond the scope of this study.  Further studies examining the 
cytokine profile and wound closure relationship are indicated. 
Allo-MSCs were chosen for this study rather than auto-MSCs. Although allo-MSCs are MHC-I 
and MHC-II negative in vitro12, MHC surface expression upregulates after allo-MSCs engraft 
and interact with endogenous mononuclear cells, leading to early rejection and stimulation 
of an immune response by the host71–74.  Likewise, in vivo allo-MSCs have been shown to 
stimulate an immune response in equine studies12,70,71.  Regardless, allo-MSC therapy still 
has favourable outcomes equable or nearly equable to auto-MSC therapy73,75, and allo-MSC 
therapy has had favourable outcomes in equine experimental synovitis63,76 and naturally 
occurring arthritis studies77,78 .  Furthermore, allo-MSCs collection is not invasive to the 
recipient, and they can be characterized, expanded, then cryo-stored long term, allowing 
prompt administration during the acute inflammatory stage when MSC therapy may have 
its most advantageous effects, unlike auto-MSCS that can take many weeks to be 
expanded18,62,78–80.  Thus, allo-MSC therapy has value in the clinical setting for unanticipated 
urgent surgical procedures and unexpected injuries. 
There were several challenges met in this study.  First, the total amount of cells 




a variation of 1.05 x 108 cells.  We conducted previous feasibility studies with smaller 
amounts of cells and determined that a viability rate of 80% was expected following 
transportation of the cells (See Chapter 4).  However, on arrival the first two shipments had 
viability rates of 60% and 66%, far below the anticipated 82% viability achieved in the 
third shipment rate.  No explanation for the variation in viability rates was immediately 
apparent, other than acknowledgement of the fragile nature of expanding and transporting 
large amounts of live mammalian cells.  Admittedly, this may be a confounding practicality 
for clinical practice.  Regardless, the effective cell dose to modulate the inflammatory and 
healing response is unknown, and even the lowest administered dose in our horses was 
three times higher than previously highest administered IV dose71, and cumulatively a 
positive effect was seen with increased contraction, decreased epithelialization and 
decreased overall wound size.  Second, we intentionally did not check for cross-mismatch of 
the administered cells to the recipient horses.  It is possible the three treatment horses that 
did not have a clinically adverse response failed to react because their haplotypes matched 
the MHC of the donor cells.  However, this is extremely unlikely considering the donor cells 
were pooled from five separate donors and horses have upwards of twenty-nine different 
haplotypes121, although it is possible that the degree of clinical adverse reaction could be 
related to whether there was a MHC mismatch of only one donor compared to all five.  
Third, the mRNA expression levels of the cytokines were measured rather than the 
translated functional proteins. Messenger RNA expression does not necessarily equate 
similar fold change expression of a functional protein, as the actual expressed protein can 
be quite variable from the measured mRNA.  However, recent studies have determined that 
in mammalian cells in a state of homeostasis, an mRNA to protein expression ratio can be 
predictably measured for different genes across all tissues, with 85% of a proteins 
translation being determined at the mRNA level149.  In addition to the decreased technical 
complexity, improved measurement accuracy, and decreased cost of measuring mRNA 
using multiplex assay technology compared to other methods such as qPCR139,140, an 85% 
accuracy in predicting protein expression based off measured mRNA can be considered an 
acceptable screening tool before quantifying actual protein expression using more 
expensive and technically challenging methods such as ELISA.  Finally, the small sample size 




and detecting statistical significance amongst the tested variables.  A larger sample size 
with adequate power would allow for better statistical analysis and firmer conclusions. 
Although administering this amount of IV allo-CB-MSCs is feasible, ultimately it did not 
accelerate time to wound closure or improve histologic quality of healing. However, the 
treated horses had significantly reduced epithelialization on day 14 and a trend for 
increased contraction as well as an overall reduced mRNA expression for several cytokines.  
There are financial and logistical implications that likely would limit the clinical usefulness 
of IV allo-CB-MSCs for wound healing, particularly in horses that are otherwise healthy and 
probably would have healed satisfactorily anyways.  However, IV allo-MSC therapy may 
have more benefits in horses that are truly immunocompromised, or in those that have 
sustained large wounds with an inappropriate inflammatory response, rather than small 
surgical wounds created in a controlled environment.  Techniques that may further 
increase the effectiveness of IV allo-MSC therapy include priming or preconditioning MSCs 
prior to administration20,87,117,150, repeating injections79,93, and administering cells via 
regional limb perfusion89,94,96. 
6.5 Conclusions 
This is the first equine study to demonstrate changes in wound healing following IV MSC 
administration.  Furthermore, in this study the highest ever dose of MSCs, intravenous or 
otherwise, was administered to equids.  We achieved our primary objectives of 
administering 1.51 – 2.46 x 108 CB-MSCs intravenously and showed that large doses of IV 
allo-CB-MSCs can be administered with minor transitory adverse clinical reactions, at least 
in this subpopulation of horses, contrary to our hypothesis. The reasons for these adverse 
reactions are unknown, and were also seen in one control horse and may be related the cell 
suspension solution, MHC mismatch, and/or hyperkalemia.  In addition, horses that 
received allo-CB-MSCs had smaller dermal scar size overall characterized by a trend for 
more contraction and significantly less epithelialization on day 14, which may provide a 
cosmetically and functionally superior repair, although the time to wound closure and 
quality of histologic repair were not improved, again contrary to our original hypothesis.  
We also met our secondary objective of measuring gene expression of several 




in expression after IV allo-CB-MSC therapy, and although exploring the significance of these 
variations was beyond the scope of this study, initial findings suggest that there is a general 
anti-inflammatory effect that may have influenced final dermal scar size.  At this time, we 
cannot recommend IV allo-CB-MSC therapy as the sole treatment for improving cutaneous 
wound outcomes, although further research may demonstrate support its use as ancillary 
therapy in complicated wounds or immunocompromised patients when paired with basic 
good wound management.  Further studies are needed to describe the profiles of immune 
modulators involved in wound healing and how IV MSC therapy alters their expression, and 
to determine ideal effective doses, route of administration, number of treatments, and 






7.  GENERAL DISCUSSION AND FUTURE EXPERIMENTS 
We are able to report the highest dose of IV MSCs administered to an equine; first 1.02 x 108 
allo-CB-MSCs in the pilot project (see Chapter 4) followed by 1.51 – 2.46 x 108 allo-CB-MSCs 
in the main study (see Chapter 6).  This is two to five times higher than the other highest 
reported dose by Williams et al.71.  In the pilot project, neither of the mares had any adverse 
reactions, and tolerated the injection well.  However, in the second study, 3 of the treatment 
horses (50%) had reactions and, surprisingly, one of the horses in the control group (17%).  
Although recognized as a possibility, this was not entirely expected as the horses in the pilot 
project did not have a response and all the previous reports of horses receiving IV MSCS via 
the jugular or palmar digital vein did not report a clinically detectable response12,64,71,89,94–
96.  The reactions are consistent to what is reported to occur with antigenic stimulation 
during a plasma or whole blood transfusion in horses, and our horses responded 
appropriately when the infusion was slowed151.  However, this does not account for the 
response seen in the single control horse.  The formulation of the HTS-FRS is not publicly 
available, but has similar concentrations of intracellular electrolytes including potassium to 
preserve mammalian cells during shipping71,146.  HTS-FRS is not formulated for IV infusion 
use, but part of the intention of Williams et al.’s study was to determine if HTS-FRS was a 
safe medium for IV administration because separating and then re-suspending CB-MSCs in 
saline can cause increased cell death71.  Our treatment of sixty mLs of 50% diluted HTS-FRS 
delivered over fifteen minutes is a low rate and well below the safe mg/kg/min dose of 
potassium, although some individuals may be sensitive to additional IV potassium.  In 
addition, as the HTS-FRS formulation is currently unknown, it’s possible it may contain a 
preservative or other additive that the single control horse responded to.   
Pulmonary injury is a potential complications following IV MSC infusion21,91.  Even though 
none of the horses developed any complications for the remainder of both studies, we 
cannot ascertain that there was no damage to the lungs because no histopathology was 
performed on lung tissue. A full necropsy and subsequent histologic examination would 
have been interesting but was deemed ultimately unnecessary as the horses had no other 
clinical symptoms apart from the initial infusion reactions.  However, the subject horses 




injury that may affect their future athletic performance and welfare.  Further investigation 
into the safety of IV HTS-FRS and IV MSCs with larger numbers of horses, histopathology, 
and long term follow up is needed.  
For the first time in the equine literature, we are able to report evidence of homing and 
engraftment of allo-CB-MSCs to cutaneous wounds in horses following jugular IV 
administration (see Chapter 4).  As far as the authors are aware, there are no comparable 
studies in the equine literature examining tracking of MSCs and cutaneous wounds. 
Although not necessary to promote healing16,17,79,80,85, engraftment of MSCs at the site of 
injury is considered beneficial for secretion of immune mediators and have a local 
paracrine effect to promote healing16,84,86,87. There are several different avenues to enhance 
engraftment including delivery method, priming and preconditioning the cells, and 
preconditioning the host environment. 
Compared to regional limb perfusion (RLP) and direct intralesional injection, IV delivery 
appears to have the lowest rates of engraftment16,152.  Using a natural occurring 
tendinopathy clinical trial, Becerra et al. tracked technicium99m-labelled MSCs using 
nuclear scintigraphy following IV jugular administration and found that there was no 
homing of cells to the tendon lesion, small amounts following RLP, and the most after direct 
intralesional injection152.  However, the horses were only administered 1.0 x 107 MSCs and 
the injuries were not considered acute152, both factors that would negatively influence 
homing and engraftment16,86,87.  Homing and persistence of MSCs seems to be most efficient 
with direct intralesional injection in tendons in horses96,119,152,153.  However, direct 
intralesional injection can be used only if the lesion is discrete and accessible by needle, and 
there is concern that injecting a substance into already compromised tissue may cause 
further iatrogenic injury to the tissue16,88,89.  RLP can successfully deliver MSCs to an active 
lesion, and although homing and engraftment appears to be less efficient than direct 
injection96,152, RLP may be more advantageous in cases where the lesion cannot be easily 
accessed with a needle, such as in the hoof capsule, or where there is diffuse disease or 
injury while decreasing the risk of an adverse response from large doses of jugular MSCs.  
Furthermore, fewer cells may be required to have the same effect as jugular IV 




successful homing and engraftment of MSCs is possible following IV administration, 
exploring other delivery methods such as RLP may deliver the same beneficial effects while 
avoiding possible systemic adverse reactions. 
Preconditioning the CB-MSCs prior to injection may have increased the engraftment 
observed in the pilot project (see chapter 4).  The purpose of preconditioning is to either 
increase the cells’ efficiency in homing and transendothelial migration, and/or improve the 
resilience to rejection in the host tissue by exposing the cells to certain conditions and 
substances86,87,117.  Exposing the cells to hypoxic conditions prior to injection preconditions 
them to tolerate a hypoxic environment and causes upregulation of CXCR4, a receptor 
necessary for transendothelial migration86,87.  In an equine wound model, however, hypoxic 
preconditioning did not enhance wound healing, although evidence of engraftment was not 
examined20.  Other preconditioning or priming methods include exposure to anti-oxidants, 
statins, and interferon, and gene therapy to prevent premature apoptosis and to upregulate 
surface receptors to enhance engraftment86,87,117.  Methods to precondition the host tissue 
to be more reception to foreign MSCs include irradiation, post-ischemia conditioning 
through repeated restriction of blood flow following MSC administration, and systemic 
statins87.  Further studies examining the effects and of feasibility of preconditioning of MSCs 
and the host tissue in the horses with limb wounds is warranted. 
In the main project, IV allo-CB-MSCs did not accelerate time to wound closure nor improve 
the histologic healing score, although over all days there was a decrease in the non-haired 
dermal scar size characterized by an overall increase in contraction and decrease in 
epithelialization, with significantly less epithelialization on day 14 (Figures 6.4 - 6.7).  In 
laboratory animals, MSC therapy has been shown to accelerate time to wound closure, 
enhance contraction, and promote angiogenesis and re-epithelialization15,17,142. Similarly, in 
an equine study, direct dermal injection of CB-MSCs reduced the histologic inflammatory 
score and accelerated reduction in the wound area, although time at complete wound 
closure was not recorded20. Reduction of the total non-haired dermal scar size is considered 
beneficial as the repair would be more cosmetic, durable and less prone to reinjury.  
Although benefits in dermal scar size were appreciated in both our studies, perhaps direct 




delivery in order to avoid potential systemic adverse reactions, to reduce the number and 
therefore cost of CB-MSCs therapy, and to improve engraftment rates.   
In this study, a single dose of CB-MSCs was administered in the acute phase of wound 
healing, which has been shown to have more beneficial effects than dosing in later following 
injury18,62,73,78–80. However, several studies in other species have shown that repeat doses 
have even more beneficial effects than a single acute dose79,93.  An equine wound model 
using repeat doses of MSCs during the acute inflammatory, inflammation resolving, and 
remodelling phases would be interesting to determine whether increasing dosing regimens 
would further enhance healing and wound closure. 
Intravenous allo-CB-MSCs suppressed the mRNA expression of all cytokines in limb wounds 
except for the antifibrotic cytokine, TGFβ3 (Figures 6.8 – 6.12).  Determining the direct 
relationship between the cytokines and the macroscopic and histologic characteristics of 
wound closure was beyond the scope of this project, but there are some interesting 
differences in the cytokines profile of equine limb wounds following IV MSC infusion 
compared to other studies.  In laboratory animal models that received MSC therapy shortly 
after injury, cytokine profiles typically had a decrease in proinflammatory mediators, but 
increase in anti-inflammatory and profibrotic mediators15,16,84,142, in contrast to the 
decrease in anti-inflammatory and profibrotic cytokines that we measured.  Limb wounds 
in horses share inflammatory characteristics with those of chronic wounds in humans; 
specifically, a low-grade protracted inflammatory response increases the chance for 
infection and impairs epithelialization, angiogenesis, and contraction4,15,24,142.  MSC therapy 
has been shown to trigger the transition of chronic wounds from a proinflammatory and 
proliferative cytokine environment to one that resolves of inflammation and promotes 
remodelling16,142.  In an acute limb wound in the horse, the initial inflammatory response is 
less robust than what is seen in thoracic wounds, and it’s believed that a restricted initial 
inflammatory response is inadequate to trigger the cascade of cytokines required for 
resolution of inflammation and transition into each of the sequential phases of healing, 
leading to a chronic non-healing wound and the formation of EGT4,24.  Following IV CB-MSC 
administration in our study, expression of inflammatory mediators was overall lower 




expression on day 2, and positive effects on dermal scar size were still appreciated.  This is 
in contrast to the theory that limb wounds need more initial inflammation to promote 
healing.  Comparing the local cytokine environment of limb wounds to thoracic wounds 
with and without treatment with IV MSCs will further help us understand the role of MSCs 
and the cytokine environment in wound healing, and will be described in future 
manuscripts using samples collected from thoracic wound during this study. 
Normal healthy horses were used in these studies, and although positive changes were 
seen, the measured improvement in the wounds was relatively minor and may not be worth 
either the expense of the procured allo-CB-MSCs or the risk of adverse reactions and 
pulmonary injury for wounds that likely would have healed normally anyways.  However, 
IV MSC therapy in horses with chronic non-healing wounds may have more benefits.  MSC 
therapy has been shown to help resolve refractory wounds in humans by decreasing 
proinflammatory cytokine expression while increasing the expression of the anti-
inflammatory cytokines IL-4 and IL-10, consequently promoting granulation tissue, 
contraction, and epithelialization15,142.  MSC therapy as a sole or concurrent therapy to basic 
chronic wound management in horses warrants further investigation. 
EGT is a fibroproliferative disorder and shares many similarities with keloid formation in 
humans38,46.  There is some evidence to suggest that keloids formation may be driven by an 
autoimmune reaction or hypersensitivity response to components of sebum or glandular 
structures when the skin is injured48,50.  A similar process may also potentially be a 
component in EGT formation in horses, and research examining EGT for characteristics of 
an autoimmune response and the potential use of immunosuppressive antifibrotic drugs 
such as intralesional interferon48 and tranilast154 would be interesting. 
Messenger RNA of the inflammation-associated proteins βarr2, CXCL8/CXCR2, and 
CXCL10/CXCR3 were identified for the first time in equine cutaneous tissue (see Chapter 5), 
and initial findings suggest that there are differences in expression for βarr2 and 
CXCL8/CXCR2 in wounds of the limb compared to the thorax (Figure 5.1), although these 
suspicions have to be repeated on a larger group of horses that have not been administered 




the progression and resolution of inflammation in wound healing25,26, and several studies 
have repeatedly shown that deficiencies in the proinflammatory CXCL8/CXCR2 axis early in 
wounding, or the inflammation resolving CXCL10/CXCR3 axis later on can lead to a delayed 
wound healing and pathologic scarring25,26,29,135,155.  Cytokine-based strategies to influence 
the interaction of chemokines with the wound environment can promote a normal course of 
healing, such as preventing ligand-receptor binding by administering chemokine and/or 
receptor specific antibodies and administering “decoy” non-functional chemokines26.  In 
addition, preventing or promoting cell surface receptor expression for these chemokines by 
altering βarr-mediated intracellular signalling is also very promising130,156.  For example, 
blocking βarr2-mediated upregulation of CXCR2 can prevent chemotaxis of neutrophils and 
help resolve chronic inflammation of wounds, while still allowing production of CXCL8 to 
promote angiogenesis and epithelialization130.  One common pharmaceutical that has been 
shown to alter the inflammatory environment of wounds is gentamicin.  Gentamicin is an 
aminoglycoside antibiotic that in addition to having antimicrobial properties, has also been 
shown to increase expression of CXCL10 when applied topically in ultrahigh doses in a pig 
wound model157, and thereby can potentially resolve neutrophilic inflammation while 
promoting M2 macrophage and lymphocyte infiltration and stopping angiogenesis.  This 
study was performed in the context of skin grafting and thus was not recommended in the 
acute stages of wound healing when neovascularization is vital.  However, this mechanism 
may be beneficial in chronic equine limb wounds, where halting the protracted 
inflammation of neutrophil infiltration and stopping granulation tissue proliferation 
through angiostasis could potentially resolve or prevent EGT formation, and has the added 
benefit of being widely available and relatively inexpensive compared to other 
pharmaceutical and regenerative therapies.  These mechanisms of altering chemokine-
mediated inflammation has potential in promoting healing and resolving inflammation of 
chronic wounds in horses and warrants further investigation.   
Other novel therapies that have promising results in altering the wound environment and 
improving healing in laboratory animals may also help resolve chronic wounds in horses.  
These strategies include gene therapy to increase or decrease the expression of cytokines to 




maintain MSCs and other inflammatory mediators at the wound site158.  As far as the author 
is aware, these therapies have not been applied to wound healing in horses, and merits 
further consideration and may provide further valuable ancillary treatment options to 







8. GENERAL CONCLUSIONS 
Following the administration of >1.51 - 2.46 x 108 allo-CB-MSCs, limb wounds had 
decreased wound area size characterized by increased contraction and decreased 
epithelialization, but did not accelerate the time to wound closure or improve the quality of 
repair or inflammation histologically.  The cytokine profile was altered within these 
wounds to have less expression of proinflammatory, anti-inflammatory, inflammation 
resolving, and profibrotic mediators, which is in contrast to the current belief that more 
acute inflammation at the time of injury followed by rapid resolution of inflammation, 
similar to what is seen in body wounds, would result in improved healing of limb wounds.  
Unexpectedly, half of the horses that received CB-MSCs and one of the placebo injected 
control horses experienced infusion reactions, although the reactions were relatively minor 
and resolved quickly when infusion was slowed, and did not experience any further 
reactions for the duration of the study.  However, the minor improvement in wound healing 
and observed reactions brings into question whether the administration of this high of a 
dose is worth the expense or the risk of an adverse systemic reactions to promote wound 
healing in otherwise normally progressing wounds, although it may be of benefit in horses 
with chronic refractory wounds.  In addition, because necropsies and histopathology were 
not performed, and the horses were not followed long term, we cannot state that there 
were no immediate or long-term consequences.  Further research to avoid these 
disadvantages of IV allo-CB-MSC therapy in equine cutaneous wound healing include 
delivery by RLP, preconditioning the cells and the host tissue prior to injection, and 
repeating doses throughout healing.  Other therapies that do not involve MSCs and may 
benefit wound healing include the use of immunosuppressive antifibrotic medication and 
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